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EXECUTIVE SUMMARY 
 
 
Kottmann, Linda M. Chemoprevention for Primary Breast Cancer Risk Reduction for 
Women at High Risk of Breast Cancer: Implementing an Evidence-Based 
Recommendation. Unpublished Doctor of Nursing Practice capstone project, 
University of Northern Colorado, 2016.  
 
 This capstone project was an evidence-based quality improvement project with 
three objectives: (a) to understand current practice of primary breast cancer 
chemoprevention in an integrated health system; (b) to evaluate the most current evidence 
available and the U.S. Preventive Services Task Force’s (2013) Breast Cancer: 
Medications for Risk Reduction recommendation; and (c) to plan for implementation of 
the recommendation as a clinical practice guideline and evaluate the guideline outcomes 
through a future pilot study.  The pilot study was not part of the capstone but included for 
planning purposes. 
 Evidence exists of the effectiveness of selective estrogen receptor modulators and 
aromatase inhibitors for risk reduction of primary breast cancer for women at high risk 
for the development of breast cancer.  Recommendations have been published by national 
prevention and oncology organizations advocating use of these pharmacologic agents in 
the high-risk female population.  Despite good evidence, the use of medications to 
prevent breast cancer among women at high risk has not been put into practice.  
 Local data support that women at high risk of breast cancer have not been 
educated about nor offered medications to reduce their risk.  A Delphi method was used 
to understand obstacles to recommendation of chemoprevention and strategies to 
iv 
 
facilitate discussions with high-risk women.  The development and implementation of a 
clinical practice guideline for breast cancer risk reduction would increase use of current 
evidence consistent with national standards of care, inform women of options for breast 
cancer risk reduction, and engage healthcare providers in shared decision-making with 
women relevant to breast cancer risks.  
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CHAPTER I 
 
 
STATEMENT OF THE PROBLEM 
 
 
Introduction 
 
Breast cancer is a significant public health problem (Howell et al., 2014).   
Second only to skin cancers, breast cancer is the most common malignancy diagnosed in 
U.S. women (American Cancer Society [ACS], 2016b; DeSantis et al., 2015; Smith et al., 
2015).  In Colorado, breast cancer is the most commonly diagnosed cancer with 33.4% of 
diagnosed cancers attributable to the breast (Colorado Department of Public Health & 
Environment, 2016).  For 2016, the ACS (2016b) estimates approximately 246,660 new 
cases of invasive breast cancer; 61,000 new cases of carcinoma in situ; and 40,450 breast 
cancer deaths among U.S. women.  Only lung cancer causes more cancer deaths in U.S. 
women (ACS, 2016b; DeSantis et al., 2015).  Women fear breast cancer due to familiar 
statistics such as one in eight or 12% of women will be diagnosed with invasive breast 
cancer in their lifetime (ACS, 2016b; DeSantis et al., 2015).  Epidemiologists note the 
lifetime risk represents an average of risks of different women as breast cancer is not 
normally distributed in populations; most women have a low lifetime risk of less than 4% 
and the remaining women have risks from 4% to 80% (DeSantis et al., 2015; Evans et al., 
2012).  
Most women who develop breast cancer have no known risk factors beyond age 
and being female (ACS, 2016a; Genetic Home Reference, 2016).  Subsets of women 
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have the highest risk for breast cancer.  Association with familial breast or ovarian 
cancers accounts for approximately 15–20% of all breast cancers; of these, 5–10% are 
hereditary (ACS, 2016a).  Information about risks might be particularly useful when 
making decisions about screening (Nelson et al., 2012) and advising women how to 
reduce their risk with lifestyle or pharmacologic modalities (Howell et al., 2014).  
Individuals with a family history of breast cancer might be at higher risk for breast cancer 
depending on presence of breast cancer in a first degree relative; number of relatives who 
had developed breast, ovarian, or a related cancer; age at which breast cancer was 
diagnosed in the relative; and age of the individual (ACS, 2016a; National 
Comprehensive Cancer Network [NCCN], 2016; National Institute for Healthcare 
Excellence [NICE], 2015).  This increased risk is due to shared genetic and/or 
environmental risks.   
Background and Significance 
Katapodi, Dodd, Lee, and Facione (2009) revealed through a correlational cross 
sectional study of 184 English speaking women in a metropolitan setting on the western 
coast of the United States that most women underestimate their risk of breast cancer.  Of 
women at high risk for breast cancer, 89% underestimated their actual risk (Katapodi et 
al., 2009).  In a United Kingdom study assessing individual risk for diseases, 95% of 
women indicated they wanted to know their breast cancer risk (Evans et al., 2012).  Many 
women at high risk might be eligible for risk-reducing interventions (Evans et al., 2012; 
Vogel, 2015).  
There are evidence-based risk assessment strategies to identify women at higher 
than average risk for breast cancer (Nelson et al., 2012; NICE, 2015; Sestak & Cuzick, 
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2015; Tice et al., 2008; Tyrer, Duffy, & Cuzick, 2004).  Use of these modalities, e.g., a 
clinical practice guideline (CPG) or a screening tool, to identify women at higher risk 
could allow for personalized care and education, interventions for prevention, early 
detection of disease, and decreased mortality (CRA Health, 2016).  
Once identified, women who are at higher than average risk for the development 
of breast cancer could benefit from risk reduction strategies including preventive medical 
therapy commonly called chemoprevention.  Surgical strategies such as prophylactic 
mastectomy and bilateral oophorectomy, although highly effective, were not addressed in 
this capstone.  Freedman et al. (2003) estimated as early as 2003, as many as 15% of 
women age 35 to 79 might be eligible for tamoxifen chemoprevention.  Howell et al. 
(2014) noted the risk and prevention panel involved in the Breast Cancer Campaign of 
2012 estimated based on the relevant literature, nearly 50% of breast cancers could be 
prevented in women at high and moderate risk.  Prevention of breast cancer in women at 
high risk could be achieved through the use of evidence-based preventive medications, 
specifically tamoxifen, raloxifene, exemestane, and anastrozole (Howell et al., 2014).   
Instructing all women in lifestyle measures including weight loss or limiting peri-
menopausal and postmenopausal weight gain, regular exercise, and moderate 
consumption of alcohol could reduce breast cancer risk by approximately 30% (Howell et 
al., 2014).  Additional health recommendations to reduce breast cancer included 
encouraging longer breastfeeding for overall health benefit to mother and baby, which 
might include a modest reduction of breast cancer risk in mothers (Howell et al., 2014).  
As early as 1976, Sporn, Dunlop, Newton, and Smith of the National Cancer 
Institute in Bethesda coined the term “chemoprevention” as “the use of pharmacologic or 
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natural agents that inhibit the development of invasive cancer either by modifying 1) the 
initiation phase, or 2) the progression phase (otherwise known as the latent period or 
period of neoplasia)” (p. 1332).  Cazzaniga and Bonanni (2012) expressed the current 
state of understanding risk-reducing medication: 
Although the precise mechanism or mechanisms that promote a breast cancer are 
not completely established, the success of several recent clinical trials in 
preventive settings in selected high risk populations suggests that 
chemoprevention is a rational and an appealing strategy.  Breast cancer 
chemoprevention has focused heavily on endocrine intervention using selective 
estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs).  
Achieving much success in this particular setting and new approaches as low-dose 
administration is actually under investigations in several topics.  Unfortunately, 
these drugs are active in prevention of endocrine responsive lesions only and have 
no effect in reducing the risk of estrogen-negative breast cancer.  Thus, recently 
new pathways, biomarkers, and agents likely are to be effective in this subgroup 
of cancers and were put under investigation.  Moreover, the identification of new 
potential molecular targets and the development of agents aimed at these targets 
within cancer have already had a significant impact on advanced cancer therapy 
and provide a wealth of opportunities for chemoprevention. (Abstract) 
 
A model of effective population risk reduction was found in cardiovascular health 
improvements by identifying individuals at risk and use of medications to reduce 
atherosclerosis and blood pressure (Howell et al., 2014).  As with cardiovascular disease, 
treatment for breast cancer has improved over the past three decades, leading to reduced 
death rates for both diseases.  Unlike cardiovascular disease, there is no direct feedback 
loop for breast cancer (Seidman, 2012).  In cardiovascular disease treatment, blood 
pressures decrease and cholesterol levels decline with medication; there is no similar 
direct marker for breast cancer.  Breast cancer deaths have decreased by nearly 33% over 
the past two decades (Howell et al., 2014).  Despite this success, primary prevention of 
breast cancer has not been enacted at the population level as has occurred with 
cardiovascular disease (Howell et al., 2014).   
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Problem Statement 
The following problem exists: women at increased risk for primary breast cancer 
due to strong family histories, genetic mutation, or personal atypical biopsies are not 
routinely and consistently being offered preventive therapy despite evidence that such 
therapy could reduce breast cancer by one quarter (Amir, Freedman, Seruga, & Evans, 
2010) or by one-third to nearly 50% (Cuzick et al., 2014; Howell et al., 2014; Vogel, 
2015).  This capstone project evaluated current use of chemoprevention and queried 
subject matter experts (SMEs) regarding an evidence-based recommendation for use by 
clinicians in a large integrated managed care organization (MCO; Kaiser Permanente 
Colorado, 2016) to consider the use of pharmacological risk reduction interventions for 
women at high risk for breast cancer.  
Chemoprevention Is Underused in  
Clinical Practice  
The American Society of Clinical Oncology (ASCO; 2013) reviewers concluded:  
Research is needed to address the many unresolved issues related to the poor 
uptake of breast cancer chemoprevention agents in women who are at increased 
risk. These include (1) the design of effective tools and approaches to educate 
providers on the option of chemoprevention, (2) efficacious interventions that 
communicate to eligible women the risks and benefits of specific 
chemoprevention agents, (3) the development of tools that more accurately 
identify women at increased risk, and (4) a greater understanding of what 
disparities and barriers exist with regard to chemoprevention use among women 
at higher risk for breast cancer. (Visvanathan et al., 2013, p. 2960) 
 
Many women are unaware of their personal risk for breast cancer (Vogel, 2015). 
The literature acknowledged difficulty in accurately identifying women at risk (Amir et 
al., 2010).  For some individuals, family medical history is unknown. Murff, Spigel, and 
Syngal (2004) conducted a meta-analysis of 14 studies on family history of cancer and 
found the patient report of first degree family members with breast cancer was accurate at 
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about 80% with family members’ medical history while the patient reported family 
history agreement with gynecologic cancers was significantly lower.  Some family 
history was lost to present-day patients as people were reluctant to discuss their medical 
conditions, particularly those involving cancer (Domchek & Antoniou, 2007). 
Limitations of risk assessment tools for breast cancer, the tool’s validation in populations, 
and limited discriminatory accuracy presented challenges to clinicians wanting to advise 
patients on chemoprevention (Amir et al., 2010). 
Once identified as high risk for breast cancer through validated risk assessment 
models such as the National Cancer Institute’s Breast Cancer Risk Assessment Tool 
(BCRAT--the modified Gail model; Gail et al., 1999), BRCAPRO (CRA Health, 2016), 
or the Tyrer-Cuzick (International Breast Cancer Intervention Study [IBIS]; Tyrer et al., 
2004) model, women are not consistently and routinely informed of the availability of 
risk reduction interventions (Ozanne et al., 2013; Vogel, 2015).  This issue is addressed 
in detail in this capstone.  
Financial Impact: Cost of Breast  
Cancer Care 
Costs for breast cancer care and treatment are substantial.  Kaiser Permanente 
Colorado’s (2016) partner in another geographic region with a larger population has been 
keen to identify women with a predisposition for breast cancer in order to offer genetic 
counseling for education and genetic testing, intensive surveillance, chemoprophylaxis, 
and surgical strategies for risk reduction.  In the business case for comprehensive risk 
assessment screening of adult women, the Interregional Breast Cancer Leaders group 
projected a significant financial savings and quality of life improvement compared to 
usual care:  
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Finding just the adult women carrying BRCA that we don’t know about in our 
membership today will enable them to make choices to avoid 4,000 plus cases of 
breast and ovarian cancer allowing us to give $13,000 plus quality adjusted life 
years back to our members and their families.  The benefit of this 
multidisciplinary approach is estimated to be $306 million NET from avoided 
cancer treatment costs. (S. Kutner, personal communication, October 15, 2015) 
 
Challenges, Problems, Situations, and Opportunities  
Leading to the Capstone Project  
 
If breast cancer in high-risk women can be reduced by up to 50% through 
medication for risk reduction, why is this clinical strategy not more widely embraced?  
Several reasons were exposed in the literature.  Clinicians and health consumers fear 
health risks and adverse events from medications (Vogel, 2015).  Patients perceive 
selective estrogen receptor modulator (SERM) risks to be greater than benefits as well as 
perceiving SERM side effects as greater than their personal risk of breast cancer 
(LaCroix et al., 2010).  Patients fear endometrial cancer out of proportion to its true 
tamoxifen-related risk; there is no endometrial cancer risk with raloxifene (Vogel, 2015).  
The concept of probabilistic as compared to absolute risk is confusing (Malenka, Baron, 
Johansen, Wahrenberger, & Ross, 1993; Vogel, 2015).  At-risk women make decisions 
for chemoprevention based on their lived experiences, which carry more weight than risk 
probabilities (Holmberg, Waters, Whitehouse, Daly, & McCaskill-Stevens, 2015).  The 
experience of observing a loved one suffer through breast cancer treatment only to 
succumb to the disease might be a strong motivator to some women or a deterrent to 
screening and detection for others (Holmberg et al., 2015). 
Ropka, Keim, and Philbrick (2010) reported healthcare providers have biases 
against use of medications for risk reduction of primary breast cancer.  Lack of 
reasonably accurate and feasible methods for assessing personal individual risk and lack 
  8 
 
 
 
of established risk thresholds that maximize benefit  and minimize harms curtail wide 
spread use (Vogel, 2015).  Menopausal hormone replacement therapy (HRT) is still 
widely used by post-menopausal women and cannot be used with a SERM (Vogel, 2015).  
The Patient Protection and Affordable Care Act of 2010 (Health and Human Services 
[HHS], 2015) required health insurance plans to cover counseling about chemoprevention 
for women at higher risk of breast cancer.  Beginning January of 2014, SERM medication 
costs have been covered for chemoprevention of primary breast cancer in high-risk 
women (Sebelius & Wasserman Schultz, 2014).  
Population estimates indicated as many as 15% of women age 35 to 70 years 
might be eligible for tamoxifen chemoprevention (Freedman et al., 2003).  Complete 
Health Solutions (formerly Population and Prevention Services) of Kaiser Permanente 
Colorado lists 154,514 women ages 40 to 74 years enrolled as members in the health plan 
as of July, 2016 (A. Bayer, personal communication, July 15, 2016).  Using Freedman et 
al.’s (2003) 15% estimate, roughly 23,177 women could be eligible for chemoprevention 
within the health system, which is an astounding number of women. Other studies 
suggested lower population estimates.  An additional challenge was side effects to the 
medication limited their broad appeal.  One quarter to 40% of trial participants 
discontinued chemoprevention due to adverse effects (Cuzick et al., 2013). 
Factors Favoring Chemoprevention  
Uptake  
 
Involvement in a clinical trial promotes primary breast cancer chemoprevention 
(Smith et al., 2016).  Receiving a physician recommendation for risk-reducing 
medications is effective (Smith et al., 2016).  The patient-perceived quality of clinician 
communication, such as having all questions answered by a physician, and perceiving the 
  9 
 
 
 
clinician supported their understanding of risk-reducing therapy, is a significant predictor 
of uptake (Rondanina et al., 2008). 
Clinicians want help with determining benefits and risks of risk reduction 
medications and how best to communicate these with women (Collins et al., 2014). 
Freedman et al. (2011) developed a risk/benefit index to facilitate patient education and 
shared decision-making regarding raloxifene and tamoxifen for postmenopausal women 
with and without a uterus.  Their color-coded chart was designed to help providers select 
women in whose benefits from chemoprevention outweighed risks and, conversely, 
women in whom harms would restrict medication use.  Education and support for all 
providers caring for women at higher risk for breast cancer is needed (Butow & Phillips, 
2016).  Recommendations for communication to patients include using absolute risk over 
relative risk estimates, i.e., “4 in 1000 women over 5 years will get a blood clot due to 
tamoxifen rather than tamoxifen doubles the risk of a blood clot” (Butow & Phillips, 
2016, p. 554; Forrow, Taylor, & Arnold, 1992; Malenka et al., 1993).  Heisey, Pimlott, 
Clemons, Cummings, and Drummond (2006) encouraged healthcare providers to utilize 
the term risk reducing medication rather than chemoprevention because it was less likely 
to lead women confusing these medications with cancer chemotherapy. 
Limitations of Risk Reducing Medical  
Therapy for Women at High risk of  
Breast Cancer  
 
Colditz, Wolin, and Gehlert (2012) summarized the critical barriers to change for 
the prevention of cancer in general.  These could be applied to breast cancer: 
(a) skepticism that cancer can be prevented,  
(b) the short-term focus of cancer research,  
(c) interventions deployed too late in life,  
(d) research focus on treatment not prevention,  
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(e) debates among scientists,  
(f) societal factors which affect health outcomes,  
(g) lack of transdisciplinary approaches, and  
(h) the complexity of successful implementation. (p. 127) 
 
Despite data that document a decrease in incident breast cancer with SERMs and 
AIs, these prophylactic medications did not decrease breast cancer deaths based on 
300,000 person years of follow up (Cuzick et al., 2013).  The IBIS-1 revealed no 
differences in deaths between tamoxifen and placebo groups at a p value of 0.8 and non-
statistically significant excess deaths in the tamoxifen arm 5.1% versus 4.6% at a p value 
of 0.4 (Cuzick et al., 2013). 
Harms of Risk Reduction Medications:   
Life Threatening, Serious Events, and  
Other Events 
 
Adverse effects (AEs) or toxicity of SERMs and AIs include life threatening 
effects and impacts on quality of life.  Life-threatening effects of tamoxifen, raloxifene, 
exemestane, and anastrozole include stroke, pulmonary embolism, deep vein thrombosis 
(DVT), and endometrial cancer. 
 Pulmonary embolus: Data from the National Surgical Adjuvant Breast and 
Bowel Study and the Breast Cancer Prevention Trial revealed an increase in 
pulmonary embolus among tamoxifen participants--risk ratio 3.01, 95% CI 
1.15 -9.27 (Fisher et al, 1998); 1,449 women over 50 years of age would 
need to be treated to cause one case of pulmonary embolus (Mahoney, 
Bevers, Linos, & Willett, 2008, p. 355).   
 Risk of venous thrombotic events (VTE) increased: tamoxifen relative risk 
(RR) 1.93 and raloxifene RR 1.60 (Nelson, Smith, Griffin, & Fu, 2013). 
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 Risk of endometrial cancer--tamoxifen RR 2.13. The number needed to 
harm (NNH) is 437 women older than 50 years who would need to be 
treated to cause one case of endometrial cancer (Mahoney et al., 2008, p. 
355).  Raloxifene RR is 1.14 (95% CI 0.65 – 1.98; Freedman et al., 2011).  
 Increased risk for cataract development with tamoxifen use (risk ratio 1.14 
95% CI 1.01-1.29; Fisher et al., 1998); 323 women would need to be treated 
with tamoxifen to cause one cataract (Mahoney et al., 2008).   
Adverse events reported among placebo controlled trial participants included hot 
flashes (77.7% of users of tamoxifen versus 65% of placebo users, respectively); night 
sweats (66.8% versus 54.9%; Day et al., 1999); depression among 45%; insomnia; 
vaginal dryness (40% of users); and decreased libido (Vogel, 2015).  
 Aromatase inhibitors worsened bone mineral density (Cuzick et al., 2014). 
Overall, 25-40% of trial participants discontinued chemoprevention due to AEs.  
The pharmacogenomics of tamoxifen CYP2D6 enzyme metabolism indicated some 
women were poor metabolizers and other ultra-rapid metabolizers of the medication 
(Goetz, Kamal, & Ames, 2008).  Not all women have the same response to therapy.  
Universal genetic CYP2D6 testing could make use of the SERM cost prohibitive.  An 
agreement to recommend women test for pharmacogenomics could not be reached; a 
Food and Drug Administration Advisory Committee recommended indicating on the 
package insert that variability in metabolism occurs with the medication (Goetz et al., 
2008). 
 Aromatase inhibitors (AIs) block estrogen synthesis and are active only in 
post-menopausal women as the primary source of estrogen is conversion in 
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peripheral tissue as opposed to ovarian synthesis in pre-menopausal women 
(Mocellin, 2016).  
 Overinflated stated benefits according to some researchers due to breast 
cancer overdiagnosis--a term for detection of non-significant, non-life 
threatening breast cancers noted due to aggressive screening programs 
(Prasad & Diener–West, 2015). 
Theoretical Framework: The Stetler Model 
The Stetler model (2001) is an evidence–based practice model used for project 
planning and implementation.  It includes five phases and their purposes. The model is 
useful to describe translation of evidence into practice (Stetler, 2001).  The model 
outlines steps of utilization of evidence to facilitate practice.  The following steps were 
used to guide this capstone:  
 Phase I: Preparation.  This phase is comprised of project formulation, 
presentation of the capstone proposal to the capstone committee, and 
presentation to the Institutional Review Boards (IRB) of the healthcare 
organization (see Appendix A) and the university (see Appendix B). 
 Phase II: Validation. This phase includes evaluating the literature on 
chemoprevention for breast cancer, comparing the integrated healthcare 
organization’s experience with the literature, and using highest levels of 
evidence whenever possible, e.g., systematic reviews, meta-analysis, and 
randomized controlled trials (RCTs).  Descriptive sources were also used as 
sources of evidence. 
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 Phase III: Comparative Evaluation/Decision Making.  The Delphi method 
was used with subject matter experts to elucidate the obstacles and 
facilitators to implementation of chemoprevention and to develop a vision to 
overcome these barriers.  
 Phase IV: Translation/Application.  This phase includes developing and 
implementing a clinical practice guideline for primary breast cancer 
chemoprevention for high-risk women within the health system.  
 Phase V: Evaluation (Stetler, 2001).  This phase includes assessing the 
chemoprevention recommendation value to the organization, women 
members, and to healthcare providers, which will be done through a pilot 
study (not a part of the capstone). 
Elements of Kaiser Permanente Colorado (the Organization) that supported 
evidence-informed practice included (a) leadership support; (b) the capacity to engage 
evidence-informed practice, specifically an effective implementation framework; and (c) 
infrastructure to support and maintain the culture of evidence-informed practice (Stetler, 
2001).  Key leadership for this work included the regional obstetrics and gynecology 
Value Advisor, the radiology department Value Advisor, the women’s health governance 
council, the Breast Leaders group, and the Breast Cancer Screening Work Group 
(BCSWG).  An implementation framework is in the planning stages in this project.  The 
infrastructure to support and maintain evidence-informed practice is well established in 
the Organization as evidenced by the electronic clinical library and decision support tools 
for clinicians.  
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Literature Review 
A comprehensive literature review undertaken to research the evidence included  
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Elton B. Stevens 
Company (EBSCO), PubMed, Cochrane Database of Systematic Reviews, and Google 
ScholarTM for breast cancer chemoprevention.  A search for a chemoprevention guideline 
within the health plan clinical library was undertaken.  Keywords included breast 
neoplasm, breast cancer, risk screening, risk reducing medication, prevention of breast 
cancer, chemoprevention, primary breast cancer, women at high risk for breast cancer, 
and female.  The focus was on high quality evidence from the current and past five years 
with inclusion of important earlier RCTs, systematic reviews, and descriptive studies to 
complement the evidence related to this capstone. 
Clinical Practice Recommendation 
The U.S. Preventive Service Task Force (USPSTF) 2013 Breast Cancer: 
Medications for Risk Reduction endorsed clinicians’ engagement with women at 
increased risk for breast cancer regarding use of tamoxifen and raloxifene to reduce their 
risk of breast cancer.  Nelson et al. (2013) designated this recommendation Grade B 
evidence, indicating there was a high degree of certainty that the net benefit would be 
moderate or a moderate certainty that the net benefit would be moderate to substantial 
(see Appendix C). 
The USPSTF (2013) recommended primary care providers screen all women 
patients with any family history of breast, ovarian, tubal, or peritoneal cancer with one of 
several simple screening tools as a first step in identifying the need for genetic counseling 
and possible genetic testing for BRCA1 or BRCA2 deleterious genes (Moyer, 2014).  
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The target population for screening is asymptomatic women 35 years of age and older 
without a history of breast cancer, ductal carcinoma in situ (DCIS), or lobular carcinoma 
in situ (LCIS; Moyer, 2014). 
The Breast Referral Screening Tool (B-RST; Bellcross, Lemke, Pape, Tess, & 
Meisner, 2009) is an easy to use electronic questionnaire that Traxler et al. (2014) 
demonstrated public health nurses could incorporate into screening.  On average, this 
screening added five minutes to the nurse’s care encounter (Traxler et al., 2014).  The 
screening calculates a negative result (not at increased risk for a genetic mutation 
contributing to breast cancer) or a positive finding (a 5-10% chance or greater of having a 
genetic mutation contributing to breast cancer).  Positives are then referred to a genetics 
counselor for a more thorough assessment of risk and possible genetics testing for 
BRCA1, BRCA2, PTEN, TP53, and potentially other deleterious genetic mutations 
(Traxler et al., 2014).  The screening program is readily available on-line in open access 
(Emory University, 2012). 
A commonly-used population screening tool is the modified Gail model (now 
referred to as the NCI’s Breast Cancer Risk Assessment Tool [BCRAT]) for 
identification of women who might be at higher than average risk for breast cancer 
(Constantino et al., 1999).  A calculated risk of 1.66% or greater for breast cancer in the 
next five years would indicate increased breast cancer risk above the population risk 
(Howell et al., 2014, Nelson et al., 2013; USPSTF, 2013).  Due to medication toxicity 
risk, USPSTF (2013) cautiously advised preventive treatment based on a 3% five-year 
risk instead of the 1.66% (Howell et al., 2014; Nelson et al., 2013).  Risk/benefit tables 
developed by Freedman et al. (2011) were developed to guide determination of 
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medication use based on age, race or ethnicity, and hysterectomized status of the woman 
(Howell et al., 2014).  
The USPSTF (2013) recommended use of 
 Tamoxifen when benefits are greater than risks for women 50-59 years of 
age whose estimated five-year risk of invasive breast cancer is 4.5% or 
greater (determined by BCRAT; NCI, 1999; Nelson et al., 2013; Vogel, 
2015). 
 Raloxifene when benefits are greater when estimated five-year risk 
according to the BCRAT is 
o greater than 2% among women in their 50s,  
o 3% among women in their 60s, and 
o 4% among women in their 70s (Nelson et al., 2013; Vogel, 2015). 
Primary prevention trials with placebo controls indicated tamoxifen and 
raloxifene reduced the incidence of invasive breast cancer by seven to nine cases per 
1,000 women over a five-year treatment period (Nelson et al., 2013).  Individuals with 
the highest risk derived the most benefit with the two SERMS (Nelson et al., 2009).  
Oncology organizations support the USPSTF (2013) recommendation.  The 
American Society of Clinical Oncology (ASCO; 2013) guideline recommended women 
35 years or older with a five-year breast cancer risk greater than 1.67% discuss as an 
option the use of tamoxifen, raloxifene, and exemestane to reduce the risk of estrogen 
receptor (ER)-positive breast cancer.  The ASCO’s report included a systematic review of 
randomized controlled trials and meta-analysis published between 2007 and 2013, 
encompassing 19 trails and six risk reduction medications (Visvanathan et al., 2013):  
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 Specifically, ASCO recommended high-risk women age 35 or older be 
advised of the option of tamoxifen 20 mg per day for five years to reduce 
the risk of ER-positive breast cancer. 
 For post-menopausal women, raloxifene 60 mg per day for five years and 
exemestane 25 mg per day for five years should be discussed as options for 
breast cancer risk reduction (Howell et al., 2014). 
 High risk is defined as individuals with a five-year projected absolute risk of 
breast cancer of more than 1.66% (based on the BCRAT or equivalent 
measure) or women diagnosed with lobular carcinoma in situ (Howell et al., 
2014). 
 Selective estrogen receptor modulators are contraindicated in women with a 
history of DVT, pulmonary embolus, stroke, or transient ischemic attack, or 
during prolonged immobilization, or in combination with HRT (Howell et 
al., 2014). 
  The United Kingdom National Institute of Health and Care 
Excellence (NICE; 2015) guideline for women at increased risk of breast 
cancer by virtue of family history of disease recommended that women with 
a greater than 30% lifetime risk (1 in 3-4+) of breast cancer be offered 
tamoxifen or raloxifene and those with a greater than 17% (1 in 6+) lifetime 
risk should consider preventive therapy.  Aromatase inhibitors were not 
endorsed at the time of their guideline publication (IBIS-II was not yet 
published) but NICE did advise a lifestyle handout be provided (Howell et 
al., 2014).  
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The National Comprehensive Cancer Network (NCCN; 2016) published 
guidelines for breast cancer risk reduction; it acknowledged the difficulty of estimating 
breast cancer risk for an individual.  Women and their healthcare providers must weigh 
demonstrated benefits with health risks of the interventions--surgical strategies such as 
bilateral mastectomy or, in some cases, bilateral oophorectomy.  Chemopreventive 
interventions include SERMs and AIs.  The NCCN recommends use of the modified Gail 
model (BCRAT) to assess breast cancer risk in women 35 or older:  
Women determined to be at increased risk for breast cancer with a life expectancy 
of ten or more years should have counseling, specific to the individual, to reduce 
breast cancer risk.  Risk reduction surgery is recommended for BRCA1 and 
BRCA2 mutation carriers and risk reduction medications are recommend for 
individuals without contraindications to the medication. (MS-6)  
 
The NCCN (2016) recommends tamoxifen as a superior choice of risk reduction 
for most postmenopausal women who want non-surgical approaches to lower their breast 
cancer risk.  Subject matter experts (Vogel et al., 2010) concluded tamoxifen had 
continued risk reduction after cessation of therapy whereas raloxifene showed diminished 
benefits.  Results of the Breast Cancer Prevention Trial (BCPT; Fisher et al., 1998), 
indicated a subpopulation of women with atypical hyperplasia (AH) or lobular carcinoma 
in situ (LCIS) had significant benefits outweighing risks with tamoxifen.  The NCCN 
experts on the Breast Cancer Risk Reduction Panel strongly recommended 
chemoprevention for these women.  It was recommended that high quality evidence from 
randomized controlled trials (RCTs) be used when counseling high risk women on the 
risks, benefits, and alternatives to risk-reduction medications—e.g., information from the 
BCPT, the study of tamoxifen and raloxifene (STAR), Mammary Prevention 3 (MAP.3; 
Goss et al., 2011), and IBIS-II trials (Cuzick et al., 2014; NCCN, 2016).  
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Based on findings from the BCPT (Fisher et al., 1998), the U.S. Food and Drug 
Administration (FDA) approved tamoxifen in 1999 for breast cancer risk reduction for 
women at high risk (NCCN, 2016).  In 2007, the FDA approved raloxifene to reduce risk 
of invasive breast cancer in postmenopausal women with osteoporosis or high risk of 
invasive breast cancer (Freedman et al., 2011).  In January 2014, the U.S. Department 
Health and Human Services announced tamoxifen and raloxifene as covered benefits by 
insurance plans without individual copayment for primary breast cancer risk reduction in 
women at increased risk for breast cancer with low risk of adverse effects (Sebelius & 
Wasserman Schultz, 2014). 
The American Cancer Society (ACS) guidelines for cancer prevention were 
published in 2010 (Kushi et al., 2012).  Four lifestyle recommendation were endorsed to 
reduce cancer risk overall: (a) achieve and maintain a healthy weight throughout life, (b) 
keep a physically active lifestyle, (c) consume a healthy diet, emphasizing plant foods, 
and (d) limit consumption of alcoholic beverages. All women are advised to follow these 
recommendations to lower cancer risk.  
Synthesis of the Literature 
The literature supported the recommendation for appropriate high risk women be 
informed and consider use of risk-reduction strategies to prevent breast cancer.  
Randomized controlled trials indicated SERMs (tamoxifen or raloxifene) or AIs 
(exemestane or anastrozole) lower risk of primary breast cancer (Amir et al., 2010; 
Cuzick et al., 2013; Goss et al., 2011; Nelson et al., 2013).  In SERM trials, 83,399 
participants were followed over an average period of 65 months with 306,617 years of 
follow up (Howell et al., 2014).  The aggregate reduction in all breast cancer, including 
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DCIS, with tamoxifen 20 mg per day was 38% (p < 0.001; Cuzick et al., 2013).  Trial 
data suggested an estimated 10 year decrease in cumulative incidence from 6.3% in the 
control group to 4.2 % in the SERM groups (Howell et al., 2014).  In the STAR trial, 
tamoxifen was superior to raloxifene in longer term follow-up for prevention of invasive 
breast cancer (relative risk of raloxifene to tamoxifen 1.24, 95% confidence interval 1.05- 
1.47; Fisher et al., 1998; Vogel et al., 2010).  Raloxifene contributed fewer side effects 
than tamoxifen, particularly for women with a uterus, and some researchers suggested 
raloxifene is preferable in post-menopausal women (Freedman et al., 2011; Howell et al., 
2014).  
A recent meta-analysis of risk-reducing medications for incident breast cancer 
published in the Cochrane Database of Systematic Reviews validated that the aromatase 
inhibitors exemestane and anastrozole were effective in primary prevention of breast 
cancer in post-menopausal women (Mocellin, 2016).  Placebo-controlled trials of 
exemestane reported a 65% reduction of breast cancer risk after five years of treatment 
(Goss et al., 2011).  The IBIS-II study (Cuzick et al., 2014) compared anastrozole to 
placebo; 3,864 post-menopausal women 40 through 70 years of age at increased risk of 
breast cancer were randomly assigned to anastrozole one milligram per day or placebo 
for five years.  The incidence of breast cancer declined by 53% in anastrozole users 
(hazard ratio 0.47, 95% CI 0.32 to 0.68; Cuzick et al., 2014).  Health risks of aromatase 
inhibitors did not include thromboembolic risk and endometrial cancer; yet they were 
associated with mild to moderate myalgia and arthralgia and reduced bone density 
(Cuzick et al., 2014; Howell et al., 2014).  
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Waters, Cronin, Graubard, Han, and Freedman (2010) estimated only 2% of 
eligible women opt for chemoprevention.  A systematic review of uptake of primary 
breast cancer chemoprevention in 26 studies encompassing 21,423 women revealed 
higher utilization in clinical trials (25.2%, 95% confidence interval [CI] 18.3-32.2) than 
in non–trial settings (8.7%, 95% CI 6.8-10.9).  The pooled uptake estimate was 16.3%, 
95% CI 13.6-19.0 (Smith et al., 2016). 
The largest risk reduction in breast cancer occurs in the first five years (Cuzick et 
al., 2013) and the duration of benefit might last 20 years (Butow & Phillips, 2016; Smith 
et al, 2016).  Cuzick and colleagues (2013) reported the number needed to treat (NNT) to 
prevent one case of incident breast cancer is 40-60.  Vogel (2015) cited a NNT of 42 to 
prevent one incidence of breast cancer using data in the same meta-analysis.   
Among women at highest breast cancer risk with BRCA 1 and BRCA 2 gene 
mutations, tamoxifen decreased risk among women with BRCA 2 by 62 % (Fisher et al., 
1998; King et al., 2001) with no effect among BRCA 1 mutation carriers who are more 
likely to develop ER-negative neoplasms (Goss et al., 2011; Stuckey & Onstad, 2015).  
Although evidence indicated SERMs and AIs could reduce the incidence of primary 
breast cancer, data are lacking that risk reduction by SERMs or AIs reduces breast cancer 
deaths (Moyer, 2014; Nelson et al., 2013; Visvanathan et al., 2013).  
Freedman et al. (2011) developed a risk-to-benefit index to quantify benefits from 
chemoprevention with tamoxifen or raloxifene for breast cancer prevention in post-
menopausal women.  This benefit to risk index complemented clinical evaluation for 
decision-making for initiation of chemoprevention.  The indices were based on 
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background risks in populations of White, Black and Hispanic women 50 years of age 
and older with and without a uterus (Freedman et al., 2011).  
Summary 
 
Not all women have equal risks for the development of breast cancer.  Women 
identified as high risk for breast cancer are best served by a comprehensive patient-
centered discussion with a healthcare provider knowledgeable in appropriate surveillance 
and risk reduction strategies.  Randomized controlled trials, systematic reviews, and 
meta-analysis of RCTs provide high quality evidence of the effectiveness of tamoxifen, 
raloxifene, exemestane and anastrozole for primary breast cancer risk reduction in 
women at increased risk of breast cancer.  A weakness of current processes is a perceived 
lack of knowledge among women and their care providers about risk reduction 
medications.  Additionally, a gap in care exists with the low uptake of these medications 
in women who could benefit.  
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CHAPTER II 
 
 
PROJECT DESCRIPTION 
 
 
Purpose of the Doctor of Nursing Practice Project 
 
The purpose of this Doctor of Nursing Practice (DNP) capstone project was to 
assess the current state of chemoprevention for women at high risk of breast cancer at the 
managed care organization and the evidence and applicability of the 2013 USPSTF 
recommendation to discuss and offer medications for breast cancer risk reduction as well 
as design a pilot study to implement the recommendation based on subject matter 
experts’ consensus. 
Project Objectives  
1. Obtain baseline information on the current use of chemoprevention for high- 
risk women at Kaiser Permanente Colorado (the Organization). 
2. Evaluate the most current evidence available and the U.S Preventive Service 
Task Force’s (2013) Breast Cancer: Medications for Risk Reduction 
recommendation and its applicability to the population in the managed care 
setting. 
3. Plan how to implement the recommendation as a clinical practice guideline 
and evaluate the guideline outcomes through a pilot study. 
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Objective One 
Data from pharmacy records from September 1, 2015 through September 20, 
2016 were gathered utilizing International Classification of Disease (ICD) codes.  The 
ICD-10 and ICD–9 codes were used as the year under evaluation included the time of 
transition from ICD– 9 to ICD-10 in October 2015 (see Table 1).  There were 37 
prescriptions for tamoxifen, raloxifene, exemestane, and anastrozole for women without a 
current or past diagnosis of breast cancer.  This number of prescriptions provided the 
baseline.  The author acknowledges the limitation of this process; despite steps to isolate 
prescriptions specifically for women who do not have cancer currently or a past 
diagnosis, women taking these medications for prevention of recurrent disease might 
have been included in this baseline number.  Additional baseline data were obtained 
through the author’s pilot survey of women members at a specific obstetrics and 
gynecology group practice within the Organization. 
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Table 1 
 
International Classification of Disease Codes Indicative of Women Taking Risk- 
Reducing Medications for Primary Breast Cancer at Kaiser Permanente Colorado 
 
Diagnosis ICD-9 code ICD- 10 code Number of 
prescriptions 
Family history of malignant 
neoplasm of breast 
 
V16.3 Z80.3 7 
Genetic susceptibility to 
malignant neoplasm of breast 
a) BRCA 1gene mutation 
positive 
b) BRCA 2 gene mutation 
positive 
 
V84.01 Z15.01 1 
 
3 
 
3 
Family history of carrier of 
genetic disease 
 Z84.81 None found specific to 
this code 
 
Lobular carcinoma of breast in 
situ of unspecified breast 
 
 D05.00 0 
Lobular carcinoma in situ of 
right breast 
 
 D05.01 1 
Lobular carcinoma in situ of left 
breast 
 
 D05.02 3 
Atypical ductal hyperplasia 
(ADH) 
610.8 610.8x Atypical ductal 
hyperplasia unspecified  
None found specific to 
this code 
 
Atypical ductal hyperplasia, 
right breast 
 
 610.1x 9 
Atypical ductal hyperplasia left   610. 2x 9 
 
High risk for development of 
breast cancer (nonspecific) 
(Fine, Gittleman, & 
Kobbermann, 2015) 
 
611.9 N64.9 None found 
Personal history of therapeutic 
irradiation 
 
 Z92.3 None found 
Family history of ovarian cancer 
 
 Z80.41 1 
Total RX   37 
Other ICD-10 codes: Z80.41, Z80.49, Z85.3, Z85.43  
(Codes largely obtained from Fine et al., 2015; www.icd10data.com; prescriptions at 
KPCO from T. Delate, personal communication, September 22, 2016). 
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The Organization’s breast cancer screening clinical practice guideline (Williams, 
2013) recommended performing a risk assessment for all women beginning at age 40 and 
repeating at least every five years.  Similar to the BCRAT model (NCI, 1999) and the B-
RST (Emory University, 2012), the guideline asks about personal and family history of 
breast cancer.  A convenience sample of 200 women was screened using the MCO’s 
clinical practice guideline for risk assessment; the lower age range was moved to 30 to 
identify young women who might have risk factors. The guideline (Williams, 2013) 
defined high risk as  
 Personal history of breast cancer including lobular and DCIS 
 Breast biopsy showing atypical hyperplasia, atypical apocrine metaplasia, or 
lobular hyperplasia (LCIS) 
 A first degree relative of either sex (parent, sibling or child) diagnosed with 
breast cancer 
 Documentation of an inherited genetic alteration associated with increased 
breast cancer risk 
 Blood relative with documentation of an inherited genetics alteration 
associated with increased breast cancer risk.  
The Breast Cancer Screening Work Group added women who had had mantle 
field chest irradiation at age less than 30 for Hodgkin’s lymphoma as a high risk group as 
these individuals’ risk for breast cancer was substantially higher than the general 
population (ACS, 2016a; NCCN, 2016).  This risk factor was added to the questionnaire. 
Of 200 women screened, 56 women (28% of the sample) indicated at least one of 
the above risk factors.  Five of the 200 women (2.5%) had a prior or current diagnosis of 
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breast cancer.  If these five women were excluded, 25.5% of the group (51 women) 
indicated some factor that could increase their risk.  Upon review of the women’s 
responses, six women were referred to adult genetics for counseling and determination of 
fit for genetic mutation carrier testing.  These six women comprised 3% of the group 
surveyed and 10.1% of those with any positive screening response.  Eleven women of the 
200 had previously been referred to hereditary cancer genetics.   
Objective Two 
A literature review was done using CINAHL, Pub Med, EBSCO Host, Cochrane 
Database of Clinical Trials, and Google ScholarTM.  High quality and high level evidence 
was sought, specifically systematic reviews or meta-analyses of randomized controlled 
trials (RCTs) for use of medications to reduce primary breast cancer risk.  Other levels of 
evidence obtained and reviewed included well-designed RCTs--level II, well-designed 
controlled trials without randomization--level III, well-designed observational cohort 
studies--level IV, descriptive and qualitative studies--level V, and expert opinion--level 
VI (Melnyk & Fineout-Overholt, 2015, p. 92).  Focus on the literature was from the past 
five years with inclusion of important guiding research from earlier dates. 
A Delphi survey was undertaken to ascertain subject matters experts’ (SMEs) 
opinions on chemoprevention of primary breast cancer for high-risk women in the 
population of adult women at the integrated health system.  The findings from the Delphi 
survey comprised the strategy for development of a clinical practice guideline (CPG) for 
the Organization.  A pilot study is planned to evaluate the outcomes of the clinical 
practice guideline (not actually undertaken for this capstone).  
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Objective Three 
A Delphi survey in two rounds was undertaken to ascertain subject matter 
experts’ opinions on chemoprevention of primary breast cancer for high risk women in 
the population of adult women at Kaiser Permanente Colorado.  The findings from the 
Delphi surveys were incorporated into the clinical practice guideline (CPG) along with 
the evidence from the literature (see Appendix G).  The Guideline for Risk-Reducing 
Medication for Women at High Risk of Breast Cancer is designed to facilitate counseling 
and prescribing chemoprevention.  Included in the guideline are identification of 
appropriate high risk women, evidence about risks/benefits and alternatives to risk 
reducing medications, resources for education of women, and direct orders for 
consultation and medication.  The guideline will be reviewed for approval for the clinical 
library by members of the Women’s Health Quality Council.  A pilot study is planned to 
evaluate the outcomes of the clinical practice guideline (not actually undertaken for this 
DNP project). 
Evidence-Based Project Intervention Plan 
In the literature, high risk is consistently defined as a five-year risk breast cancer 
of 1.67% or greater or a lifetime risk of breast cancer of 20% or greater from the BCRAT 
(NCI, 1999; USPSTF, 2013) or other research risk assessment tools.  Women identified 
as high risk were offered additional screening as appropriate using NCCN (2016) 
guidelines and were invited to discuss risk reduction strategies.  For this project, a Delphi 
survey was utilized to build consensus about offering risk reduction medication for 
women at high risk for breast cancer.  
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Project Design and Method 
This DNP project sought to put best evidence into practice and was non-
experimental.  No patients were directly involved and no personal health information was 
used in this project.  Demographic data and opinions from healthcare providers regarding 
chemoprevention for women at high risk for breast cancer were gathered through two 
Delphi survey rounds.  The Delphi method was selected as it has been used effectively to 
gather consensus where the literature is incomplete or the best approach is unknown 
(Hasson, Keeney, & McKenna, 2000).  Participants from various medical and nursing 
disciplines as well as pharmacy were selected to represent a cross-section of subject 
matter experts who care for women within the healthcare organization.  The questions 
were formulated to seek consensus at a level of 70% regarding the challenges to 
chemoprevention and strategies to overcome barriers.  
Awareness of women at high risk for breast cancer and mechanism of risk 
determination was necessary for this project’s implementation and success.  Traxler et al. 
(2014) implemented a population-based risk assessment of breast cancer in public health 
clinics in Georgia.  The authors aimed to address disparities in screening of African 
American women.  Women with risk factors suggesting increased breast cancer risk were 
contacted by a genetic counselor to further clarify risk and offer education and testing as 
appropriate.  In the population, 6% of women met criteria for referral to genetic 
counseling (Traxler et al., 2014).  Shah et al. (2012) implemented a risk assessment in a 
hospital-based health system to identify women at high risk at the time of mammography.  
Of 5,878 women who had a breast cancer risk assessment, 17% screened high risk 
according to the BCRAT (NCI, 1999; Shah et al., 2012).  The authors noted incorporation 
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of screening for breast cancer risk could be easily and efficiently added to screening 
mammography.  Once identified, these individuals could be offered more personalized 
surveillance and prevention (Shah et al., 2012).  The healthcare organization is taking 
steps to provide risk members with the introduction of a software tool in radiology later 
this year (Kaiser Permanente, 2016).  
Despite the published guideline within our health system, women have not 
routinely been assessed for breast cancer risk factors (Williams, 2013).  This problem is 
not unique to our health system; others (Phillips et al., 2016; Shah et al., 2012; Traxler et 
al., 2014) have sought creative solutions to perform risk assessments in primary care and 
radiology, respectively, to identify women at higher than average risk.  
In the United Kingdom, a study was undertaken to assess individual risk for breast 
cancer in comparison to an age-based population screening mechanism (Evans et al., 
2012).  Of the population of 10,000 women who consented, 1.07% (107 women) 
screened high risk by the Tyrer–Cuzick tool (also known as the IBIS risk assessment; 
Tyrer et al., 2004).  The study authors found it feasible to determine breast cancer risk 
and make decisions upon risk in the context of a population–based mammography 
screening (Evans & Howell, 2015).  If applied to women in the 40 to 74-year-old range at 
the integrated MCO where this capstone project occurred, 1.07% of 154,514 suggests 
1,653 women would be high risk.  The literature acknowledged the BCRAT 
overestimates risk and the Tyrer-Cuzick model underestimates risk as reproductive and 
family and personal history are handled differently in these two models.  Butow and 
Philips (2016) are currently developing an online tool labeled iPrevent to facilitate 
  31 
 
 
 
personalized risk calculation using established validated algorithms and communication 
(paper under review). 
Congruence with Organization’s Strategic Plan  
This evidence-based quality improvement project was undertaken at an 
Organization that focuses on population health (Kaiser Permanente).  Prevention of 
disease is a primary goal for the community of members.  The mission of the 
Organization is “to provide high –quality, affordable health services and to improve the 
health of our members and the communities we serve” (Kaiser Permanente, 2016, para. 
2).  The vision of the Organization is “to be a leader in Total Health by making lives 
better” (Kaiser Permanente, 2016, Our Vision).  The strategic plan includes maintaining 
competitiveness in the healthcare marketplace, controlling costs, and meeting member’s 
health care quality and service needs while ensuring a highly competent work force (S. 
Martinez, personal communication, May 12, 2016).  The Organization’s value compass 
places the member (patient) in the center with spokes for best quality of care, most 
affordable, best service, and best place to work. Specific women’s health goals for 2016 
include improvement in patient satisfaction scores as a measure of service and 
maintenance of per member/per month (PMPM) costs. This capstone project might 
improve patient satisfaction through the inclusion of personalized breast health as part of 
comprehensive women’s care.  Affordability might ultimately be improved with breast 
cancer risk assessments in contrast to age-based breast cancer screening if, over the long 
run, risk awareness leads to prevention and early detection or disease.  The 
Organization’s partner in another region submitted a business case for risk-based 
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screening with projected cost savings over the current state of care (S. Kutner, personal 
communication, October 15, 2015).  
Timeline of Project Phases 
 Phase 1 Preparation:  
o Topic identified--September, 2015 
o Capstone committee formed--October, 2015 
o Capstone committee approved--December, 2015 
o Capstone proposal approved--December, 2015 
 Phase II Validation: Literature search and analysis, revise, and hone project--
Spring, 2016 
 Phase III:  Comparative Evaluation/Decision Making--Spring to summer, 
2016 
o Approval from the healthcare organization IRB--August, 2016 (see 
Appendix A) 
o Approval from the University of Northern Colorado IRB--September 
2016 (see Appendix B) 
o Proceed with the Delphi survey of SMEs--September to October, 2016  
o Written DNP project completed and submitted—October, 2016 
o Oral Defense of Capstone--October, 2016 
 Phase IV: Translation/Application: Plan for implementation of guideline—
winter to spring, 2017 
 Phase V: Evaluation of guideline through pilot project--Spring, 2017 
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Resources  
Personnel 
The work of this capstone was done by the author with assistance from the 
research advisor and capstone committee members.  Members of the Breast Cancer 
Screening Work Group (BCSWG) within the Organization are working to improve 
identification of women at high risk of breast cancer and to utilize the latest evidence–
based surveillance techniques with this population.  This was separate from the capstone. 
The author of this capstone engaged with this Work Group in the capacity as a doctoral 
student and healthcare provider in the Organization.  The interdisciplinary Work Group 
synthesized subject matter expertise from medical imaging, primary care, women’s 
health, oncology, surgery, and population and prevention.  Some members of this 
interdisciplinary work group participated in the Delphi survey.  A research pharmacist 
was utilized for baseline data. 
Technology  
Informatics and Complete Health Solutions (2016) for the Organization were 
utilized for aggregate member information.  The informatics group is formulating a risk 
assessment mechanism within the electronic health record (EHR) to obtain risk for 
members.  Similar to the BCRAT (modified Gail risk; NCI, 1999), a calculation was 
generated based on member factors that indicated if a woman was high risk based on a 
probabilistic estimate  (this risk assessment is still in the planning phases of the Work 
Group).  The Delphi survey was distributed through Survey MonkeyTM on the 
Organization’s intranet.  Descriptive statistics were processed by the Survey Monkey 
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software and the author with guidance from her research advisor who has expertise in 
quantitative and qualitative analysis.  
Budget 
No funding was required specific to this quality improvement project.  Work was 
done on the author’s and committee member’s time.    
Market Analysis, Strategic Analysis, and Service 
Justification of Need 
The Organization and, specifically, the BCSWG have acknowledged gaps in 
identifying women at high risk of breast cancer and offering risk reduction therapies, 
which has led to the development of this DNP capstone project.  The most effective 
breast cancer screening is risk-based and not simply population-based (Amir et al., 2010; 
Evans & Howell, 2015).  Women identified as moderate to high risk need to be informed 
of their options including lifestyle changes, intensive surveillance, genetic counseling and 
testing, medications for risk reduction, and surgical prophylaxis as appropriate.    
Women want to know their risk of breast cancer (Amir et al., 2010).  Currently 
the Organization is falling behind on the clinical practice guideline and not routinely 
assessing family history or personal history of radiation therapy for Hodgkin’s lymphoma 
as risk factors.  Lack of consistent risk assessment means some women fail to have earlier 
breast imaging and are not offered risk reduction modalities or intensive surveillance.    
The cost of treating breast cancer is considerable for the woman and her family 
and for health services and public health (Evans & Howell, 2015).  This quality 
improvement project could contribute to cost efficiency over time through learning how 
to counsel high-risk women regarding chemoprevention for breast cancer within the 
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healthcare system.  Howell and colleagues (2014) asserted implementation of risk 
screening and chemoprevention would over the long term reduce breast cancer diagnosis.  
Feasibility 
The Delphi survey was a feasible method to gather opinions from healthcare 
experts involved in care of women.  As the BCSWG takes steps to close gaps in care for 
women identified as high risk for breast cancer, implementation of risk reduction 
strategies was a logical next step after risk identification. 
Sustainability 
With the development of an easy-to-use electronic risk assessment in radiology 
and in primary care, routine screening for breast (and ovarian) cancer will become the 
standard of care.  Phillips and colleagues (2016) interviewed primary care providers in 
Australia about parallels in screening for breast cancer as screening was done for 
cardiovascular health.  Themes included the desire for an easy to use endorsed risk tool 
(Phillips et al., 2016).  
Summary 
A review of baseline data in the Organization revealed female members were at 
high risk for breast cancer.  These women and their healthcare providers were unaware of 
the health risks.  The evidence indicated women at high risk were not routinely and 
consistently offered effective medications that could lower their risk.  A Delphi method 
was used to query subject matter experts in the MCO about how to address this gap in 
care.  The responses contributed to the formation of a clinical practice guideline.  
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CHAPTER III 
 
 
EVALUATION PLAN  
 
 
The purpose of this DNP capstone project was to determine how to implement the 
2013 U.S Preventive Services Task Force Breast Cancer: Medications for Risk Reduction 
Grade B evidence recommendation to offer pharmacologic agents to women at high risk 
of developing primary breast cancer at an integrated managed care organization.  No 
current evidence-based recommendation is available within the Organization (Kaiser 
Permanente, 2016) to guide healthcare providers to discuss and prescribe risk-reducing 
medications for primary breast cancer for women at high risk.  There was ample evidence 
in the literature that women at high risk of incident breast cancer should be offered 
SERMS or AIs to reduce risk.  Additional evidence was obtained from SMEs utilizing 
the Delphi method.  The author designed a quality improvement project to implement 
pharmacologic risk-reduction interventions for women at high risk of breast cancer.  Each 
of the three objectives to fulfill this purpose describes evidence–based measures and the 
method of analysis used.  
Objective One 
Objective one was to obtain baseline information on chemoprevention use for 
women at high risk of primary breast cancer at a managed care organization.  Two 
approaches gleaned this information.  An analysis of prescriptions specific to tamoxifen, 
raloxifene, exemestane and anastrozole for women without active or prior breast cancer 
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was done.  The Delphi survey was used to query subject matter experts about their 
familiarity with chemoprevention recommendations.  The measure was the baseline use 
of chemoprevention.  Outcomes would be understanding the current state and its 
significance to the population.  Tools that gathered this data were informatics in 
pharmacy and Delphi survey rounds.  Descriptive statistics were the method of analysis 
of current state information.   
Objective Two 
The second objective of the capstone was to evaluate the most current evidence 
available and the USPSTF’s (2013) Breast Cancer: Medications s for Risk Reduction 
recommendation and its applicability to our population.  The literature was reviewed for 
high quality evidence, primarily Level I--Systematic reviews and meta-analysis and 
Level II--randomized controlled trials, regarding the use of chemoprophylaxis for women 
at high risk of primary breast cancer (Melnyk & Fineout-Overholt, 2015).  Subject matter 
experts from various disciplines that care for women were surveyed about the 
applicability of chemoprevention for high-risk women at the Organization (Kaiser 
Permanente, 2016).  As an additional measure, the author compared the literature support 
for the USPSTF recommendation to the population by means of SME responses to the 
Delphi surveys.  The outcome of objective two was a synthesis of the evidence within the 
Organization and current literature relevant to medications for risk reduction. 
The Rapid Critical Appraisal (RCA; Melnyk & Fineout-Overholt, 2015) checklist 
for a randomized control trial was the method for analyzing studies’ validity, effect size, 
level of significance, and applicability (p. 546).  For systematic reviews of clinical 
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interventions or treatments, Melnyk and Fineout–Overholt’s (2015) RCA tool was used 
(p. 547). 
Objective Three 
Objective three of this capstone object was planning for implementation of the 
USPSTF (2013) recommendation as a clinical practice guideline for providers in the 
Organization and evaluation of the guideline through a pilot study (the pilot study was 
not part of this capstone project).  Tools to meet this objective were responses from the 
Delphi survey through Survey Monkey.TM   Development of a preliminary guideline was 
the outcome for objective three.  Information from the Delphi survey rounds built 
consensus toward a guideline.  Analyses of survey responses using descriptive statistics 
formed the method for this objective.  The measures resulted in quantitative and 
qualitative findings.   
Summary 
The outcome of this capstone project was the understanding of the current state of 
chemoprevention for high-risk women in the Organization (Kaiser Permanente, 2016), an 
assessment of the evidence and its applicability to the population, and the development of 
a clinical practice guideline for pharmacologic risk reduction.  
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CHAPTER IV 
 
 
RESULTS AND OUTCOMES  
 
 
 The problem statement for this DNP capstone project was women of increased 
risk for breast cancer by virtue of concerning family histories, genetic mutations, or 
personal biopsies were not routinely and consistently offered preventive therapy despite 
evidence that effective medications could reduce the risk of primary breast cancer (Amir 
et al., 2010; Cuzick et al., 2014; Howell et al., 2014; Vogel, 2015).  The first objective of 
this evidence-based quality improvement project was to obtain baseline data for the 
health system on chemoprevention used for primary breast cancer risk reduction.  The 
second objective was to evaluate the most current evidence available and the USPSTF 
(2013) grade B recommendation Breast Cancer: Medication for Risk Reduction and the 
applicability of this guideline to the population.  Objective three was to plan for 
implementation of a clinical practice guideline and evaluate the guideline through a pilot 
study (the timeline for the pilot study was after the DNP capstone project and was not 
part of the actual project).  
Objective One Outcomes  
 The first objective was met through three processes: data from the integrated 
health systems research pharmacist, information supplied by Complete Health Solutions, 
and the author’s convenience sample survey of 200 women.  It was discovered the overall 
number of prescriptions for tamoxifen, raloxifene, exemestane, and anastrozole for 
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primary prevention was low--less than 50 for a population of 154,541 women of whom 
up to 20% could have risk factors that qualified as high risk (Owens, Gallagher, 
Kincheloe, & Ruetten, 2011; Shah et al., 2012; Traxler et al., 2014).  If conservatively 
10% of the population was truly high risk of breast cancer, 15,453 women would 
potentially be eligible for risk reduction strategies; for some, this would include 
medications.  This prescribing information was evidence that use of medication to reduce 
the risk for primary breast cancer was infrequently used at the health system.  The low 
use of medication has been cited as a common problem in the literature (Vogel, 2010, 
2015; Waters et al., 2010).  Low primary prevention with medication provides an 
opportunity for improvement. 
 The number of women ages 40 to 74 in the health system is 154,541 (A. Bayer, 
personal communication, July 15, 2016).  This information was supplied by Complete 
Health Solutions (formerly Population Health and Prevention).  This was the primary 
cohort of women affected by this project; however, the author and the Breast Cancer 
Screening Work Group acknowledged the importance of identifying younger women who 
might have personal or family factors that made them high risk.  The breast cancer high 
risk registry of the Organization has 364 women known to be BRCA 1 or BRCA 2 gene 
mutation positive; a population estimate suggested there could be up to 1,800 women 
with at-risk genetic mutations in the Organization (G. Merry, personal communication, 
June 1, 2016).  The health effectiveness data and information set (HEDIS) metric for the 
Organization was 76.8% of women 50 to 74 years of age who had screening 
mammography during 2015 in compliance with USPSTF recommendations for screening 
(A. Bayer, personal communication, June 17, 2016).  According to the Centers for 
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Disease Control and Prevention’s 2015 National Health Interview Survey data, 72.6% of 
women 50 to 74 years of age reported a mammogram within the two-year screening 
interval in 2013 (Sabatino, White, Thompson, & Klabunde, 2015).  Kaiser Permanente 
Colorado mammography screening rates are consistent with this finding. 
 The author’s pilot survey was valuable to gain an estimate of the number of 
women who might be at high risk and thus eligible for genetic referral and/ or 
consideration of risk-reducing medications.  The convenience sample survey used a 2013 
clinical practice guideline (Williams, 2013) at the single Ob/Gyn practice to assess for 
personal and familial risk factors.  The findings suggested 25.5% of the population 
(51/200) had at least one risk factor for primary breast cancer requiring further 
evaluation.  Other valuable aspects of the office pilot survey included an appreciation for 
the time required for the reviewer (the author) to confirm risk assessment with members’ 
EHR documentation, follow up directly with members by e-mail or phone to clarify 
responses to the paper survey, provide education to members, determine which members 
needed referrals to genetics and enter those referrals, assess if medical information and 
family history was evident in the EHR, and update documentation when needed.  Similar 
to other health networks, the sample of women at the Organization had a subset of 
women who required further evaluation to determine if they were truly high risk and 
would benefit from additional surveillance, genetics testing, chemoprevention, or surgical 
risk reduction.  
Objective Two Outcomes  
 The second objective was a review of the current literature and the 2013 USPSTF 
guideline to recommend and offer risk reducing medication for women at high risk of 
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primary breast cancer.  The literature review and synthesis in Chapters I and II met this 
objective.  Nelson et al.’s (2013) systematic review for the USPSTF presented evidence 
for the recommendation including the following formative studies: The Breast Cancer 
Prevention Trial (Cuzick et al., 2003; Fisher et al., 1998), STAR (Vogel et al., 2010), 
MAP.3 (Goss et al., 2011), and the Multiple Outcomes of Raloxifene Evaluation (MORE; 
Cauley et al., 2001). 
  The Delphi study of chemoprevention for primary breast cancer was developed to 
learn subject matter experts’ opinions on the use of the USPSTF (2013) recommendation 
for risk reducing medications.  
Surveys 
 The author developed the first and second survey questions based on evidence in 
the literature and knowledge of the population and health system.  The purpose of the 
Delphi surveys was to gather information from subject matter experts regarding the 
USPSTF (2013) grade B recommendation for providers to discuss and offer risk-reducing 
medication to women at high risk for primary breast cancer and to use these findings to 
develop a clinical practice guideline for the Organization.  Consent for participation was 
provided with the first survey and implied panelist response (see Appendix D).  The first 
survey was available for 14 days.  Questions are available in Appendix E.  The second 
survey was designed to build toward consensus and was available for 14 days.  Questions 
are available in Appendix F.  All panel experts included in round one were invited to 
respond to round two regardless of their participation in the first round.  
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Participants 
 For this DNP capstone project, a panel of subject matter experts in women’s 
health from the disciplines of family medicine, internal medicine, Ob/Gyn, surgery, 
pharmacy, nursing, oncology, radiology, and administration were queried on the option to 
discuss and offer risk-reducing medication at the Organization.  Forty-nine health 
professionals from nine disciplines were invited to participate in the survey through the 
in-house online intranet.  Physicians, nurse practitioners, and physician assistants in the 
various disciplines were invited as were pharmacists, registered nurses in oncology, and 
care coordination in radiology and surgery.  Administrators in population health 
management, Ob/Gyn, and nursing were invited to the subject matter expert panel.  As 
the Organization covered a metropolitan region, panelists were chosen from the three 
administrative regions: the north (15 providers), the central (18 providers), and the south 
(13 providers).  The first round Delphi survey generated a 30.6 % response rate with 15 
respondents.  Fourteen of the 49 responded to round two for a 28.5% response.  Seven of 
the nine disciplines were represented in the first survey. Registered nurses might have 
identified with their specialty department, such as radiology, rather than nursing as their 
primary discipline (see Table 2).  Two survey rounds were needed to obtain the 
information.  Physicians and advanced practice nurses were equally represented among 
panelists with each group representing 40% of panelists (6/15 each group).  One each-- 
physician assistant, registered nurse, and administrator--comprised the rest of the subject 
matter experts consulted. 
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Table 2 
Demographics of Subject Matter Experts in Delphi Survey 
Discipline Number 
Invited to 
Participate 
Number of 
Participants 
Percentage 
Overall 
Total 
Participants 
Family Medicine 8 4 26.7 4 
Internal Medicine 6 0  0.0 4 
Nursing (RN) 4 0  0.0 4 
Ob/Gyn 8 5 33.3 9 
Oncology 12 1 6.7 10 
Pharmacology 3 0  0.0 10 
Radiology/Medical imaging 6 2 13.3 12 
Surgery 4 1 6.7 13 
Administration 3 2 13.3 15 
 
 
 
 By round two, there was 100% agreement that the 2013 USPSTF 
recommendation to discuss and offer SERMs and aromatase inhibitors was a reasonable 
course of care, suggesting providers could feel comfortable following this 
recommendation (Question 2, see Appendix F).  The author details how that consensus 
emerged. 
Data Collection Description 
 Data were collected between September and October of 2016 using the 
SurveyMonkey online platform program.  Questions were intended to glean opinions 
regarding the USPSTF (2013) recommendation as well as items necessary to develop a 
clinical practice guideline to enact the recommendation.  Rounds one and two of the 
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Delphi surveys were sent through the Organization’s intranet.  The majority of panelists 
responded within the first three days of the survey’s release: 46.7% (7/15) for round one 
and 71.4% (10/14) for round two.  Consensus was reached in round two for the majority 
of questions (5/7 questions; see Appendix F).  Consensus for this project was defined as 
.70 or above agreement among the responding panelists. 
Objective Three Outcomes 
 Evidence gathered for the planning of a clinical practice guideline within the 
Organization and testing the guideline through a pilot study comprised the third project 
objective.  An analysis of responses to round one questions helped form the second 
round.  The questions were structured to assess knowledge about medication use for 
primary breast cancer risk reduction and elicit opinions to guide the development of a 
clinical practice guideline.   
Round One Delphi Survey 
 In round one, question four, 71.4% of panelists (10/14) believed the Organization 
was not reaching women at high risk for breast cancer with information to help reduce 
their risk.  Comments to this question included: 
 This is the first that I have even heard of doing this. 
 Besides reminders for yearly mammograms there does not seem to be an 
advertising campaign or push through text or email to notify women. 
 
 Not sure.  I rec mammos but that is it. 
 I ask all my patients about family history of breast cancer. 
 I don't believe time allows for conversations to occur to reduce the risks. 
However, I believe we are discussing mammogram and ultrasound/MRI 
recommendations. 
 
 I am not sure what we are doing. 
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 I have had very few conversations with women about their actual numeric 
risk and I have never prescribed prophylactic treatment 
 
 I do not see this flagged on the Health Trac tab [Health Trac is a population 
health prevention reminder tab for all healthcare providers]. 
 
 The limited use of risk-reducing medications for women at high risk of primary 
breast cancer and evidence from the literature supported the development of a clinical 
practice guideline.  Eighty percent of the panelists (12/15) did not know if medications 
for primary breast cancer risk reduction were being offered or provided at the 
Organization.  Of the three panelists who indicated medications were being offered to 
reduce risk, one panelist was an oncologist, one was a breast surgeon, and the third was 
an administrator in the Ob/Gyn department.  The surgeon and oncologist added 
comments that oncology should be the service counseling and prescribing SERMs and 
aromatase inhibitors for appropriate high-risk women.  
 A follow-up question asked about current use of SERMs or aromatase inhibitors 
for high-risk women.  Nearly 80% (78.6%, 11/14) indicated the medications were offered 
by providers in other departments while 14.3% (2/14) indicated an understanding that 
providers in their department--Ob/Gyn and oncology—offered the medication.  Of the 12 
panelists who responded to question 7--“If risk reducing medications are currently 
discussed and prescribed, which discipline is doing this? (Can choose more than one 
answer),” 83.3% (10/12) indicated oncology while 25% (3/12) also indicated Ob/Gyn 
providers.  Asked whether risk reducing medications should or should not be 
recommended, 28.6% (4/14) indicated medications should be recommended more 
frequently than are currently done and none of the panelists indicated medications should 
not be recommended (see Appendix F).  One oncologist panelist (6.7%) expressed the 
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current process of offering and prescribing SERM and AIs to high-risk women was 
working adequately.  One Ob/Gyn advanced practice nurse (6.7%) indicated the current 
process was working poorly and the remainder 86.7% (13/15) did not know how well the 
current process of offering risk reducing medication to high risk women was working in 
the Organization.  
 A survey item inquiring what facilitated or hindered counseling women about 
medications for primary breast cancer risk reduction generated eight qualitative responses 
that fell into four categories:  
1.  High risk of breast cancer not identified 
 High risk women are not uniformly identified in our Organization. 
 Family hx is not adequately documented in chart.  Do not see as a dx on 
the problem list. 
 
2. Time for counseling and education of member 
 Time spent by provider, lack of knowledge. 
 Time and lack of provider knowledge (lack of personal knowledge/ 
information). 
 
3. Healthcare providers lack of knowledge 
 Not being knowledgeable about the medications hinders counseling. 
 I need more education on when to provide prophylactic therapy both 
pros and cons. 
 
 Proper guideline recommendations/cost of medicine. 
4.   Other 
 Lost to care, as many people are in and out of different insurance 
providers often. 
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 These comments were valuable for developing a guideline (see Appendix G).  In 
order to offer a medication to high-risk women, those women must be identified.  The 
Organization is in process of acquiring and implementing a software package in medical 
imaging that will solicit risk factors from women at the time of mammography.  These 
risk factors calculate a breast cancer risk score for individual woman using the 
BRCAPRO tool (Bayes Mendel lab, 2015; CRA Health, 2016).  This information is 
currently gathered on paper and scanned to the radiology information system (RIS) but 
not linked electronically to the EHR providers can access.  The Breast Cancer Screening 
Work Group, of which the author is a member, is working with Complete Health 
Solutions (2016) and information technology to develop a mechanism to quickly identify 
high-risk women who are not evaluated in medical imaging.  We anticipate a process in 
place by winter-spring 2017 as the radiology software system will be implemented at that 
time.   
 Time for risk assessment, education, and shared decision making with female 
members is a legitimate challenge in busy clinic settings.  The Organization has 
information on the Kaiser Permanente member portal to assist women in their decision to 
have a mammogram as well as decision points for women at high risk (Kaiser 
Permanente Healthwise, 2015).  Traxler and colleagues (2014) implemented a breast 
cancer risk assessment tool in public health clinics that added five minutes to the 
encounter.  Time concerns were addressed by providing the woman information to 
review and then having a follow-up phone call or in-clinic encounter for further 
discussion.  
49 
 
 The need for clinician education was addressed by various mechanisms.  In round 
two, panelists indicated a departmental in-service was their preference (76.9%, 10/13) as 
the most effective way to gain this knowledge.  One panelist commented that in addition 
to continuing medical education through a departmental in-service, having office 
champions to guide the process, Smart Rx for prescribing in the EHR, information on the 
clinical library, and an advice referral to a specialty would optimize the knowledge gain 
needed on this issue.  Another panelist indicated having a high-risk breast clinic would be 
preferred.  
 The comment about members lost to care as a hindrance to counseling could be 
partially addressed by informing the member of her breast cancer risk status.  Adding 
high risk for breast cancer to the problem list using ICD-10 (ICD10Data.com, 2016) code 
Z80.3, family history of breast cancer, or whatever diagnosis was appropriate would alert 
other care providers to her status at future encounters.  The diagnostic codes are listed on 
the clinical practice guideline to facilitate documentation for providers (see Table 1 in 
Chapter II). 
 The final survey questions in round one (questions 11 and 12) asked panelists for 
their opinion regarding the 2013 USPSTF recommendation that clinicians engage in 
shared informed decision-making with women at increased risk for breast cancer about 
medication to reduce their risk and how they envisioned implementation of the 
recommendation at Kaiser Permanente Colorado.  Responses included a range of 
comments organized into the following themes: (a) a multidisciplinary team for guidance; 
(b) primary care and Ob/Gyn providers identifying and providing medications to 
appropriate high risk women members; and (c) an infrastructure to support the change. 
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Multidisciplinary team.  Panelists commented that oncology, adult genetics, and 
clinical pharmacy would serve as consultants to primary care and Ob/Gyn clinicians 
regarding chemoprophylaxis.  An individual panelist stated, “Identify high risk woman 
by primary care, confirm by genetics, and refer to oncology or OBGYN for counseling 
medication needs.”  Others wrote about envisioning: “Use a multidisciplinary team 
working together” and “Identifying those high risk women [in primary care] and getting 
them to oncology department.”  
Primary care and Ob/Gyn role.  A panelist provided a specific comment: 
“Primary care, Ob/Gyn and surgery should have adequate information to counsel patients 
and their families about management/medication option.”  Five panelists (33.3%) wrote 
similar comments that primary care and Ob/Gyn providers could identify women at high 
risk and “provide this care.”  The USPSTF (2013) recommendation specifically stated,  
clinicians engage in shared informed decision making with women who are 
increased risk for breast cancer about medication to reduce their risk.  For women 
who are at increased risk for breast cancer and at low risk for adverse medication 
effects, clinicians should offer to prescribe risk- reducing medications, such as 
tamoxifen or raloxifene. (Recommendations, para. 1) 
  
One panelist felt specialists and not primary care were best suited to address risk-
reducing medications.  One wrote,  
Refer to a trained or educated professional who knows breast cancer and 
preventative medications, breast specialist or oncologist, possibly trained GYN 
providers who have obtained additional education about these medications, who is 
(sic) appropriate candidates. 
 
Infrastructure. One panelist wrote what was needed was a “formalized process 
in targeted departments that discuss the same information and document the same.”  
Another panelist provided a comprehensive view:  
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We need both proactive and in-reach efforts. An infrastructure should be built to 
identify those at high risk who should be offered therapy. The process can be put 
in place to proactively outreach these members and have an alert on the Health 
TRAC tab about this high risk and to consider prophylaxis. Improved education 
[is needed]. Need funding to set this. A multidisciplinary team would need to be 
assembled to address this. I believe some of this is underway. I think this care can 
be provided in OB/Gyn and primary care and oncology could be used as a 
consultative service.  
 
An additional comment from a family medicine advanced practice nurse 
addressed the need for an infrastructure with this comment; use of this recommendation  
could be done along the lines of CAD risk prevention and outreach with use a tool 
like IndiGo.  With clear clinical guidelines and recommendations.  Primary care 
could [offer & prescribe] along with support from clinical pharmacy and 
oncology.  
 
IndiGo is a population health clinical decision support tool for use at the point of care 
with patients (Doherty, 2016).  IndiGo was developed for the purpose of bringing 
evidence based practice into care. 
 One panelist wrote that members lack education around risk stratification and 
mechanisms to reduce risk.  An outreach effort such as a “know your breast cancer risk 
campaign” could be launched within the Organization to encourage members to seek out 
their personalized breast cancer risk much like cardio-vascular risks. 
 An oncologist from on the panel wrote a noteworthy comment:  
KP participated in the original NSABP trials for tamoxifen in prevention 20+ 
years ago; the long term follow up of these studies does not show an improvement 
in overall survival.  Most docs and patients don't know the actual facts of this trial 
that one needs to treat 65 women to prevent one breast cancer.  Nationwide I think 
the enthusiasm initially present to use these drugs has decreased.  I think it is 
acceptable to use in women who express interest, but I don't think it is justified or 
necessary to actively recruit more women for prevention. 
 
Despite the evidence indicating a reduced risk of breast cancer in high-risk women 
through chemoprophylaxis, these medications did not produce a decrease in breast cancer 
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mortality among women at high risk.  Some plausible explanations for this are SERMS 
reduce the rate of estrogen receptor-positive breast cancer but not hormone receptor- 
negative breast cancers (Fisher et al., 2005).  With regard to recruiting women, the author 
felt strongly women need to know their personal health risk as much as possible so if they 
choose to gain additional information from clinical experts to make informed choices. 
These points from panelists are incorporated into the clinical practice guidelines (see 
Appendix G). 
Round Two Delphi Survey 
 The Delphi survey rounds were illustrative: nearly 70% of respondents (69.2%, 
9/13) agreed that having a prompt in the EHR to screen women for high risk status was 
something they would use.  Some panelists worked in specialty disciplines such as 
oncology, surgery, and radiology and the member’s risk status was determined prior to 
the member’s encounter in their specialty department.  One panelist who disagreed 
recommended they would “rather see a prompt to complete family history, then if that is 
positive, a prompt to do proper screening and treatment.”  In the author’s pilot survey in 
an Ob/Gyn practice, family history of breast and ovarian cancer was correctly noted in 
the chart 87.4% of the time (49/56).  In the problem list of the EHR, 33.9% of those with 
risk factors (19/56) had some documentation of high risk for breast cancer such as family 
history.  The problem list was a more prominent location of important health issues for all 
health providers as documenting pertinent family history is critical to identifying women 
at high risk.  
 In response to the question--“Would you agree that having a prompt in Health 
Trac that screens for high risk status is something you would use?”, four panelists 
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answered they would not use a prompt in the EHR that screened for high-risk status.  
Two of them left the following comments: “If there were specific recommendations to 
follow” and “Unsure. It depends on what the prompt requires.” 
Specific recommendations were addressed in the clinical practice guideline.  The 
prompt included information from the current Kaiser Permanente Colorado 2013 Clinical 
Practice Guideline (Williams, 2013) about personal history of breast cancer or abnormal 
biopsy, first degree relative with breast cancer and age of diagnosis, family or personal 
history of BRCA1 or BRCA2 mutations, and radiation treatment to the chest.  
 All respondents of round two agreed following the USPSTF (2013) 
recommendation to discuss and offer SERMs and aromatase inhibitors for selected high 
risk women was a reasonable course of care.  The USPSTF recommendation formed the 
foundation of the clinical practice guideline.  Eighty-three percent (10/12) agreed primary 
care and Ob/Gyn providers with appropriate training could and should initiate the 
discussion about chemoprevention with high-risk women.  One who indicated they would 
not support primary care and Ob/Gyn initiating these discussions with high-risk women 
commented, “It seems like too nuanced a discussion to add to the PCP plate.”  The 
guideline addressed the nuances of the discussion. 
 For the development of a guideline, panelists were asked,  
Many respondents suggested having specific guidelines for discussions with 
members about SERMs and AIs for risk reduction. A clinical practice guideline 
would 
1. Indicate the mechanism for identifying women at high risk, and when that 
risk status will be reassessed;  
2. Inclusion / exclusion criteria;  
3. the medication appropriate for the woman based on her menopausal and 
health risk status, dosage, and risks/benefits, length of time of medication 
use, and management of side effects. 
4. and alternatives to the medication  
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Do you agree this forms the basis of a guideline?  If no, what needs to be 
included? 
   
There was 92.9% agreement that this information formed the basis of a guideline.  One 
panelist (7.1%) disagreed and commented, “A discussion that includes number needed to 
treat to prevent one breast cancer which is 65 and the fact that there is not a survival 
improvement with these medications.”  It is true--the evidence showed no improvement 
in breast cancer deaths with SERMs or AIs; providers and members must be informed of 
that.  Based on randomized control trials, the number needed to treat (NNT) with 
tamoxifen daily for greater than five years to prevent one breast cancer was 48 women, 
the NNT for raloxifene for four years was 112-115 women, the NNT for exemestane over 
three years was 94 women and 26 women in five years, and the NNT for anastrozole in 
seven years was 36 women (Advani & Morena Aspitia, 2014, pp. 67-68).  For 
comparison, the NNT for primary prevention of myocardial infarction with statins is 60, 
which is a widely adopted population health strategy (Taylor et al., 2013).  Women need 
to be aware of these risk and benefits to make an informed decision.  These 
recommendations from panelists have been included in the guideline (see Appendix G). 
 In round two, question 7 did not reach a consensus of opinion among panelists: 
“For planning purposes, if support is needed for these discussions with members, or the 
woman desires a second opinion, who would we refer to?”  Forty-six percent of 
respondents (6/13) selected oncology as the consultant discipline, pharmacy was the 
choice for 23% of respondents (3/13), 15.4% selected Ob/Gyn (2/13), and 15.4% selected 
genetics (2/13).  One of the 14 respondents commented they “were not sure [how to 
answer] since oncology would ideally be the first opinion.”  That panelist did not select a 
consultant discipline.  If that answer had been added to the group that selected oncology, 
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53.8% (7/13) would have chosen oncology as the discipline for consultations about risk- 
reducing medication for primary breast cancer.  The range of responses reflected no 
discipline had owned chemoprevention, thus supporting the need for a guideline.  
 In planning the implementation of the clinical practice guideline, the author 
discussed with oncologists and pharmacists regarding their comfort and willingness to 
consult on these high-risk members.  At the quarterly meeting of the Breast Cancer 
Leadership on June 1, 2016, an opinion expressed by oncologists was they would like to 
have a consultation appointment if women were interested in chemoprevention (G. 
Merry, personal communication, June 1, 2016). 
Key Facilitators and Key Barriers to Project Objectives 
Facilitators 
 Factors that facilitated the collection of information on chemoprevention within 
the health system were (a) metrics kept through an accessible pharmacy data warehouse, 
(b) the in-house communication intranet for the Delphi survey, (c) women members’ 
willingness to complete a short six question breast cancer risk assessment survey in the 
Ob/Gyn department, and (d) the ease of developing an electronic survey through the 
Survey Monkey platform.  The author believed interest in this topic from providers in 
several disciplines was instrumental in generating a response. It may have helped that the 
Breast Cancer Screening Work Group of the Women’s Health Governance Council has 
been focused on addressing breast cancer risk stratification within Kaiser Permanente 
Colorado (2015) over the same time of this DNP project (past year).  At least one health 
provider mentioned in the comments to the first round survey, “I believe some of this 
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[work] is underway” utilizing a multidisciplinary team to identify high risk members.  
The multidisciplinary team is the Breast Cancer Screening Work Group. 
 The author’s active participation on the Breast Cancer Screening Work Group 
(Work Group) might have been both a facilitator and a barrier to this DNP project.  The 
group has members from Ob/Gyn, radiology, population and prevention, oncology, 
internal medicine, and surgery.  Benefits from the Work Group included contacts with 
clinicians and administrators passionate in improving the quality of breast cancer 
screening in the Organization.  Access to genetic counseling specialists in partnering 
regions, particularly California, was helpful in the early phases of the project.  A barrier 
was the Work Group’s primary focus on identifying high-risk women evaluated in the 
radiology department.  At times, the author was pulled off track from this project by 
providing literature reviews for the Work Group on breast cancer risk assessment tools 
and strategies for care of women at moderate risk of breast cancer.  Overall, the 
experience with the Work Group has been positive and allowed for partnership in the 
development of this project.  
Barriers 
 Multiple competing demands for healthcare provider’s time are often expressed as 
a reason for limited participation in surveys.  Higher participation from oncology, 
pharmacy, and internal medicine would have added a more comprehensive view to 
responses to the Delphi surveys.  The author could have opted to invite more participants 
into the study.  The selection of participants was subject to bias and was not randomized.  
The author selected some participants from the Breast Cancer Screening Work Group as 
the topic was important to these providers.  One region’s oncology providers and 
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internists were selected by asking the author’s colleagues who would be most interested 
in this topic.  The author also selected participants whom she felt would be more likely to 
respond.  
 Obtaining the number of prescriptions for medication used as primary breast 
cancer chemoprevention was a challenge.  Understanding how to ask the question in the 
right way to get the information needed from those who have access to the data 
warehouse was crucial.  Experience from the final project in the Information Technology 
in Health course of the DNP program provided a baseline understanding of the required 
linking of clinical diagnoses with a prescription to obtain the desired results.  The author 
discovered if a prescription was not linked to an ICD-10 (ICD10Data.com, 2016) 
diagnostic code, it was not possible to track or retrieve that prescription.  A limitation of 
this project was the retrieval process might have underestimated the number of written 
orders for SERMS or aromatase inhibitors for primary breast cancer risk reduction.  
Unintended Consequences 
 An unintended consequence of this project included the author’s recognition of 
the complexity of chemoprophylaxis counseling.  Newly armed with empirical data and 
practical recommendations for discussion of risks and benefits with high-risk women, the 
author fumbled through the information she needed to convey during a scheduled patient 
appointment.  The identical twin sister of the patient was diagnosed with infiltrating 
ductal carcinoma of the breast six months earlier at age 48.  The patient wanted to know 
what steps she should take to confront this risk.  This woman was in general good health, 
was still menstruating, and took no medications.  She was scheduled every six months for 
breast imaging, alternating mammogram with breast MRI.  Her Gail (Gail et al., 1999) 
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five-year risk score was 1.8% and her lifetime breast cancer risk score was 17.3%.  Thus, 
her five-year risk met the high-risk criteria but not the 3% risk recommended by the 2013 
USPSTF recommendation to begin risk-reducing medication.  Her lifetime risk fell in the 
moderate category (20% or greater is high risk).  This education and counseling did take 
time. While developing the guideline, it became clear talking points to guide providers 
were helpful.  Teaching tools for members would also facilitate education and outreach. 
 A negative unintended consequence of this project was the time it took the author 
to settle on the appropriate DNP project topic among breast cancer concerns.  This has 
been a meandering journey.  An initial topic was breast density detected on medical 
imaging as that is a risk factor for breast cancer.  While many states have breast density 
notification laws, Colorado does not.  While discussing this with the mammography 
quality and safety manager, she mentioned an issue within Kaiser Permanente Colorado 
was creating and maintaining a registry for women at high risk for breast cancer.  At that 
point, the author became involved with the Breast Cancer Screening Work Group of the 
Women’s Health Governance Council.  The Work Group was creating a means to risk-
stratify women.  Breast cancer risks are heterogeneously dispersed among women. 
Within the Work Group, focus has been on the unaffected--women who do not have 
breast cancer but are at higher risk based on familial or personal risk factors.  A goal has 
been to identify these women and, through this project, be aware of strategies to lower 
the risk for selected women.  
 The author became interested in risk-reduction medications while reviewing the 
literature for the Work Group regarding risk screening tools. Chemoprophylaxis is an 
area of primary prevention in which advanced practice nurses can take an active role. 
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Discussion with the DNP project committee helped solidify that chemoprophylaxis of 
primary breast cancer for women at high risk was a project with sufficient complexity to 
meet the aims of a DNP capstone while also meeting the needs of the Organization.  
Individualized breast cancer risk assessment is an important topic for the Organization 
and steps are being undertaken to provide this through the use of an electronic 
questionnaire at the time of mammography.  This tool, called MagView, stratifies women 
into high (greater than 20% lifetime risk), moderate (15-19.9% life time risk), and 
average risk pools.  It is expected to be available in the first quarter of 2017.  High-risk 
women will be asked to consult with their healthcare providers (see Appendix G 
algorithm) for the next steps in care.  It is anticipated the contributions of this DNP 
project will be useful for providers and members learning of high risk status.  
Summary 
 Baseline information on current use of chemoprevention for women at high risk 
of breast cancer has been obtained (objective one).  The most current evidence for risk 
reducing medication and the USPSTF (2013) Breast Cancer: Medications for Risk 
Reduction recommendation and its applicability to the Organization’s population was 
evaluated; it was found to be relevant and of good quality.  The planning for 
implementation of the recommendation as a clinical practice guideline is underway.  The 
Delphi survey obtained valuable and pertinent opinions on willingness of providers to 
offer and prescribe SERMS and aromatase inhibitors for women at high risk of breast 
cancer and how specialists, particularly in oncology, could be used for consultation. 
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CHAPTER V 
 
 
RECOMMENDATIONS AND IMPLICATIONS 
FOR PRACTICE 
 
 
 The problem statement for this DNP project was women at increased risk of 
primary breast cancer due to personal or family histories, genetic mutation, or mantle 
field radiation at a young age had not routinely and consistently been offered preventive 
therapy despite evidence such therapy could reduce breast cancer from 25% to nearly 
50% (Amir et al., 2010; Cuzick et al., 2014, Howell et al., 2014; Vogel, 2015).  
Implications for the Organization are risk assessment for primary breast cancer could be 
routinely and consistently done.  This information would allow for the identification of 
high-risk women who can benefit from primary prevention of breast cancer.  Many 
clinicians, including the subject matter expert panel and this author, acknowledged the 
2013 Grade B recommendation from the USPSTF to discuss and offer SERMs and 
aromatase inhibitors to high risk women was a reasonable course of care.  Leadership 
within the Organization supported providers’ steps to improve breast cancer risk 
assessment to identify high risk women and offer appropriate evidence-based surveillance 
and prevention strategies as evidenced by the purchase of a new software package in 
radiology, the formation of the Breast Cancer Division, the Breast Cancer Screening 
Work Group, and this DNP project.  The recommendation from the DNP project was to 
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use breast cancer risk status to offer risk reducing medication as appropriate.  The clinical 
practice guideline will facilitate processes for the clinician (see Appendix G). 
 Key stakeholders included adult female members, particularly those with family 
history of breast and/or ovarian cancer or prior breast biopsies indicating atypical 
hyperplasia or Lobular Carcinoma in Situ or women who had mantle field irradiation to 
the chest.  New members to the Organization as well as existing members would benefit 
from a risk assessment and clear documentation in the EHR.  Additional stakeholders are 
primary care providers including advanced practice nurses and physician assistants in 
family medicine, internal medicine, and Ob/Gyn.  The clinical practice guideline 
facilitates care for women determined to be at high risk.  It is envisioned that specialists 
in genetics, surgery, oncology, and pharmacology would serve as consultants to primary 
providers.  An oncologist was the lone negative response to the Delphi survey question 
that primary care and OB/Gyn could and should initiate discussions about 
chemoprevention with high-risk women.  The oncologist expressed, It seems like too 
nuanced a discussion to add to the primary care providers’ plate,” implying education and 
orders should only be done by oncology.  It would be wise for the author to meet with 
interested oncologists to clarify if the views expressed in the Delphi survey represented 
the discipline.  Do oncologists view their role as consultants for chemoprevention or the 
primary providers of these medications to at-risk women?    
 For the DNP student author, it was clear a Delphi process was an efficient way to 
gather views from various disciplines without the challenge of getting multiple providers 
in a single setting.  This iterative process allowed for many voices on the topic (Keeney, 
Hasson, & McKenna, 2006).  A limitation of the Delphi survey method was potential 
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panelists could decline to participate as 70% of invitees did for this project.  The Delphi 
survey of nine different disciplines allowed for many opinions to contribute to a practice 
change.  A limitation of the Delphi was bias could occur toward the opinions of those 
who replied. 
 Clinical practice guidelines are based on scientific evidence but might not 
accommodate members or work environments.  The next step for implementation is to 
pilot the guideline. 
Recommendations Related to Facilitators, Barriers,  
and Unintended Consequences 
 
 As many of round one respondents indicated they needed more information about 
benefits and risks to counsel women effectively, a round two question inquired what 
respondents felt would be the best way to obtain this information.  The majority (76.92%, 
10/13) selected a departmental in-service as their way to learn with a specific comment 
from one panelist that an “adult primary care continuing medical education session” 
would be preferred.  A webinar was selected by 15.38% of respondents (2/13) and 7.69% 
(1/13) selected office champions to teach this information.  Another panelist added a 
comment that in addition to a departmental in-service would be office champions 
knowledgeable about the “Smart Rx” in Health Connect, which is the template in the 
EHR, and information in the clinical library along with a link for an advice referral to 
specialty (which specialist was not stated).  The Smart Rx would list specific orders for 
tamoxifen or raloxifene.  Those comments helped complete items needed for a guideline. 
Interestingly, one panelist stated a high-risk breast cancer clinic would be best to meet 
providers’ education needs. 
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Ongoing Activities or Evaluations Outside the Scope  
of the Doctor of Nursing Practice Project 
 The Breast Leadership Council of the Organization (Kaiser Permanente, 2015) is 
moving toward creation of a Breast Care Division to improve the member’s experience of 
breast cancer care.  Leadership has decided not to pursue a Center of Excellence 
designation at this time due to unique aspects of the Organization’s integrated health 
system (A. Weinfeld, personal communication June 1, 2016).  Other changes in progress 
include the transition to a new software system in medical imaging that plans to obtain 
risk assessment using the BRCAPRO risk tool (Bayes Mendel Lab, 2016).  This DNP 
project complemented the radiology changes as having a guideline and education 
sessions to introduce it could potentially ready providers to discuss and be familiar with 
risk reduction medications. 
Recommendations Within the Framework of the  
Organization’s Strategic Plan 
 Prevention of common health problems, early detection of disease, and risk 
reduction are hallmarks of the Organization.  In order for the membership to “Thrive” 
(Kaiser Permamente, 2016), which is the Organization’s motto, members need to be well 
informed of their personal health risks and strategies to impact those risks. 
 A supporting organization for this project was the Women’s Health Leadership 
team and, specifically, the Ob/Gyn Regional Value Advisor and the Department Value 
Advisors from radiology and women’s health, both of which serve on the Breast Cancer 
Screening Work Group.  Radiology has partnered with women’s health to plan for 
changes to breast cancer risk assessment in the Organization.  Complete Health Solutions 
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(Population Health; 2016) has been instrumental in developing strategies for 
communication with members. 
Personal Goals and Contribution to Advanced  
Practice Nursing 
 The author’s personal goals in advanced practice nursing included the ability to 
make positive changes in the healthcare environment that promote women’s health.  To 
demonstrate skills learned in the DNP program including evaluation of empirical 
evidence was another goal.  The author aimed to impact care at a broader population level 
than the individual patient encounter. The process of this DNP project has given this 
author experience in many aspects of the course work ranging from epidemiology to 
information technology to evidence-based practice to the Stetler (2001) framework as a 
theory.  The author also strove to demonstrate talents, skills, and problem solving abilities 
of advanced practices nurses with the healthcare team. 
Essentials of Doctoral Education for  
Advanced Nursing Practice 
 The American Association of Colleges of Nursing (AACN) developed the eight 
essentials for Advanced Nursing Practice in October 2006 (see Appendix H).  The goal of 
the Doctor of Nursing Practice educational program is to develop practice experts 
(AACN, 2006, p. 7).  The author incorporated many of the eight essentials into this DNP 
project, reflecting learnings over the course of study.  
Essential I is scientific underpinnings for practice.  The comprehensive and 
current literature review and analysis met this goal.   Organizational and systems 
leadership for quality improvement and systems thinking is Essential II.  This concept 
maintains an emphasis on practice, ongoing improvement of health outcomes, and 
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ensuring patient safety (AACN, 2006, p. 10).  The development of this DNP project for 
consideration of chemoprevention and a clinical practice guideline detailing how to 
implement the practice change conceptualized a new care delivery model based on 
science and was feasible within the current Organization’s political, cultural, and 
economic climate (ACCN, 2006, p. 10).  Planning for change within an organization can 
be difficult.  Partnerships with other passionate clinicians and population health specialist 
kept the energy sustained. 
 Clinical scholarship and analytic methods for evidence–based practice is the third 
Essential (AACN, 2006).  As one DNP committee member called it, “intellectual 
curiosity” has been a trait of this author.  This DNP program has helped this author 
challenge thoughts and energies into a scholarly project and translate the evidence into 
practice to meet a need in our clinical setting.  
 Use of information systems and technology and patient care technology for the 
improvement and transformation of health care, Essential IV (AACN, 2006), was evident 
in this project through the development of the Delphi surveys on the Survey Monkey 
platform, the pilot survey at the author’s clinic facility, and the need to obtain data on 
prescription use and numbers of women impacted at the Organization.  Existing decision-
making electronic tools for members at high risk could be utilized to help the individual 
woman understand her health values (Kaiser Permanente, 2015; see Appendix G for 
guideline). 
 Essential V (AACN, 2006) describes Health Care Policy for Advocacy in Health 
Care.  Several states now have breast density notification laws.  Colorado does not but 
might have such a law in the future.  Good quality evidence exists that breast density 
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increases one’s risk for breast cancer (Boyd, 2013).  Since there has been no consensus 
among researchers, clinicians, and cancer organizations on how to follow up on breast 
density noted on mammography, this was not addressed in the project.  New risk models 
will likely incorporate mammographic breast density as another factor in risk assessment 
(Boyd, 2013).  A discussion with colleagues of how breast density could be addressed in 
our system in a state that does not yet have a patient notification law began the path to 
this current DNP project topic.  This project did not create or impact healthcare policy. 
 Interprofessional collaboration for improving patient and population health 
outcomes, the component of Essential VI (AACN, 2006), was necessary to develop and 
perform this project.  The multidisciplinary team of the Work Group and the panelists 
contributed to development of the clinical practice guideline.  Population health outcomes 
will be improved through discussions between women and their providers regarding risk 
status and chemoprophylaxis for primary breast cancer prevention.  Essential VII’s focus 
was clinical prevention and population health for improving the nation’s health.  This 
project was focused on disease prevention and population health.  Advanced nursing 
practice, Essential VIII, was exemplified in this project as it met Waldrop, Caruso, Fuchs, 
and Hypes (2014) definition of the final DNP oroject as one “that should address a 
complex practice, process, or systems problem in the practice setting, (and) use evidence 
to improve practice process, or outcome” (p. 301). 
Five Criteria for Executing a Successful Doctor of  
Nursing Practice Final Project 
 Waldrop et al. (2014) described a five-point system of evaluating the final DNP 
project represented by the formula EC as PIE.  
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E equals enhances health outcomes, practice outcomes, or healthcare policy 
(Waldrop et al., 2014, p. 301).  The project enhanced practice outcomes through use of 
evidence to educate and offer a risk-reducing strategy to women at high risk of breast 
cancer.   
C equals culmination of practice inquiry (Waldrop et al., 2014, p. 302).  The 
author has become an expert on chemoprevention for high-risk women and used 
knowledge and competencies learned in the doctoral program to enact change (Waldrop 
et al., 2014, p 302).  The change is pragmatic and anticipated to be used in clinical 
practice in a timely, reproducible, and sustainable fashion.  The design for the practice 
change integrates with the EHR as recommended by Waldrop et al. (2014). 
 P equals partnerships.  Partnerships were formed through this project and the 
author collaborated on an interdisciplinary team within the Organization (Waldrop et al., 
2014, p. 302).  I equals implement evidence into practice.  It is insufficient to simply find 
and evaluate evidence--it must be applied (Waldrop et al., 2014, p. 302).  Implementation 
of the clinical practice guideline for risk-reducing medication for women at high risk of 
breast cancer is planned.  E equals evaluation of healthcare practice outcomes (Waldrop 
et al., 2014, p. 302).  Quality improvement will be evaluated on the use of the guideline. 
Criteria for evaluation are (a) does it facilitate education and care, (b) is it easy for 
clinicians to use, and (c) are more women informed of their breast cancer risk and 
strategies to lower those risks, (d) are more prescriptions written for primary prevention, 
and (e) are more referrals made to oncology for members to discuss risks and medication 
for prevention?  These factors and perhaps others will comprise the evaluation of the 
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practice change.  The evaluation process will occur after the submission of the final DNP 
project. 
Summary 
 The DNP project addressed an aspect of women’s breast health that has often 
been neglected due to the perceived complexity of the issue and difficulty identifying 
high-risk women.  There is good quality evidence, largely from randomized controlled 
trials, that SERMs and aromatase inhibitors can reduce the risk of estrogen receptor- 
positive primary breast cancers for high-risk women (Fisher et al., 1998; Goss et al, 2011; 
Vogel, 2015).  The 2013 USPSTF recommended clinicians offer and prescribe SERMs 
and AIs to women with a five-year Gail (Gail et al., 1999) risk score of 3% or greater or 
women with a 20% lifetime risk of breast cancer.  These medications are not without risk 
and do not decrease breast cancer mortality.  Women who meet criteria need appropriate 
education and counseling to make informed choices consistent with their lifestyle and 
values.  The clinical practice guideline facilitates care for these women with detailed 
information for providers and members. 
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Informed Consent - No signature document (Kaiser Permanente Colorado/ 
University of Northern Colorado) 
 
CONSENT FORM FOR HUMAN PARTICIPATION IN RESEARCH  
UNIVERSITY OF NORTHERN COLORADO 
Project title:  Chemoprevention of Primary Breast Cancer for Women at High Risk:  
  Implementing an Evidence Based Recommendation 
Student:  Linda M. Kottmann, MSN, APRN (DNP student)    
Academic Advisor Kathleen N. Dunemn, PhD, CNM, University of Northern Colorado 
School of Nursing  Phone number: (970) 351-3081/ (803) 409-8391  
e-mail:  kathleen.Dunemn@unco.edu 
Project advisor:  Kimberley Campbell, MD, Colorado Permanente Medical Group 
 
Expert Consensus via a Delphi Study 
 
The purpose of this capstone project is to evaluate the evidence on chemoprevention for 
primary breast cancer risk reduction; assess the health care organization’s current state of 
use of these medications to prevent breast cancer in women at high risk for the disease; 
and to evaluate the applicability of the 2013 U.S. Preventive Service Task Force 
recommendation to offer chemoprevention to women at high risk for primary breast 
cancer in our clinical environment. Planning how to implement the recommendation as a 
clinical practice guideline and evaluate outcomes is the final phase of this project. 
 
The Delphi method is a structured communication method that utilizes a questionnaire to 
survey experts in two or more rounds. Information from the literature review on 
chemoprevention for primary breast cancer in women at high risk is used to develop the 
first round of questions regarding the 2013 U.S Preventive Services Task Force 
recommendation.  The response from the first round will be anonymously shared with 
participants in the second round. Participants will gain additional knowledge through the 
shared responses of their colleagues.  Anonymity reduces the impact of feelings of 
embarrassment, judgements, fear of repercussions, the bandwagon effect, and influences 
of personalities dominating the process.  The Delphi method has been used in healthcare 
and other industries and is of value where there is uncertainly or lack of empirical 
knowledge.  It is anticipated that two or three rounds will be necessary but not more than 
four rounds.   All Delphi surveys will be sent and returned electronically within the 
firewall on the intranet.  It is expected that each participant wild spend approximately 15- 
20 minutes to complete each round of the Delphi process.  
 
The purpose of this e-mail is to invite your participation. Participation is voluntary and all 
responses will be kept anonymous. The data collected will be kept on a password 
protected thumb drive that is accessible only by the nurse practitioner (DNP student) and 
her advisor.  There are no foreseeable risks to participants.  This is a quality improvement 
project to evaluate the evidence for breast cancer chemoprevention and applicability of 
the 2013 U.S Preventive Service Task Force’s Breast Cancer: Medications for Risk 
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Reduction recommendation in the clinical setting. Past and existing patients will not 
benefit from this project as there is no direct intervention. The potential benefit for future 
patients is improved knowledge of risk reduction strategies for women at high risk of 
breast cancer. Future clinicians may benefit from having a clinical recommendation to 
follow.  
 
Participation is voluntary. If you begin to participate, you may decide to stop or withdraw 
at any time.  Your decision will be respected and will not result in a loss of benefits to 
which you are otherwise entitled.  If you have any questions, please contact one of the 
undersigned. 
 
Having read the above document and having had an opportunity to ask any questions, 
please access and complete the attached document, “Phase One: Delphi Study Round 
One Questions.” Please return the completed survey to me, Linda.M.Kottmann@kp.org. 
Thank you for participating in our survey. Your feedback is important. 
For my Doctoral of Nursing Practice capstone project, I am evaluating whether KP 
Colorado providers discuss and offer medications for primary breast cancer risk reduction 
for women at high risk of breast cancer.   In September 2013 the U.S Preventive Services 
Task Force published a recommendation summary as Grade B evidence "that clinicians 
engage in shared, informed decision making with women who are at increased risk for 
breast cancer about medications to reduce their risk. For women who are at increased risk 
for breast cancer and at low risk for adverse medications effects, clinicians should offer 
to prescribe risk-reducing medications, such as tamoxifen or raloxifene." As a subject 
matter expert I request your opinions to the following questions.  
Using a Delphi method I will gather the responses and submit them back to you for a 
second round to seek consensus on the process of offering risk reduction medication for 
women at high risk of breast cancer at Kaiser Permanente Colorado. 
 
Link to the recommendation: 
www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=breast (copy and paste in 
your browser) 
 
Please respond by September 15, 2016 
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Chemo-prophylaxis for primary breast cancer for women at high risk round 2 
Introduction to 2nd round 
Thank you for participating.  If you did not answer the first survey your opinion as a 
subject matter expert in women‘s health is still valued for this round of the Delphi process. 
If you get a message that the survey is closed, it means someone else is accessing it at the 
same time and you are blocked out.  If you send me a message 
at Linda.M.Kottmann@kp.org I can send you an active link. 
 
We had responses from Administration, Family Medicine, Ob/Gyn, Oncology, Radiology, 
and Surgery. We hope to have participation from Internal Medicine and Pharmacy. 
 
The goal of this round of questions is to build consensus toward the formation of a Clinical 
Practice Guideline for risk reducing medication for women at high risk for primary breast 
cancer due to personal history of atypical hyperplasia or LCIS on a breast biopsy, 
significant family history of breast or ovarian cancer (especially among first-degree 
relatives and onset before age 50 years), known personal or familial genetic mutations that 
increase risk, or “those women that have the alternating every 6 months mammogram and 
breast MRI” as one of my colleagues has said.  In general women who have an equal or 
greater than 20% lifetime risk of breast cancer or a Gail risk of greater than 1.7% risk in 
the next five years.  The 2013 USPSTF Grade B recommendation Breast Cancer; 
Medications for Risk Reduction:  
 
Recommends that clinicians engage in shared, informed decision making with women who 
are at increased risk for breast cancer about medications to reduce their risk. For women 
who are at increased risk for breast cancer and at low risk for adverse medication effects, 
clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or 
raloxifene.  
The USPSTF recommends the service. There is high certainty that the net benefit is 
moderate or there is moderate certainty that the net benefit is moderate to substantial. 
(Grade B evidence) 
 
This guideline proposed would not delete or interfere with but support the need for 
referrals to genetic counseling, intensive surveillance, or risk reducing surgery for 
appropriate women. Risk reducing medications are another option for high risk women. 
 
As a Subject Matter Expert, please respond to the following questions: 
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1. The majority of respondents felt KPCO is not reaching women at high risk for breast 
cancer with information to reduce their risk. Would you agree that having a prompt in 
Health Trac that screens for high risk status is something you would use? 
Yes 
No  
Other (please specify)  
2. Participants from round 1 felt that KPCO should recommend selective estrogen 
receptor modulators or aromatase inhibitors for primary breast cancer risk reduction to 
high risk women at KPCO. Would you agree that the USPSTF recommendation to 
discuss and offer SERMs and AIs for selected high risk women is a reasonable course of 
care? 
yes 
no 
Other (please specify)  
3. Many responded that lack of knowledge about medications for primary breast cancer 
risk reduction and their benefits & risks were barriers to counseling women about these 
options. What would be the most effective way to gain this knowledge? 
Departmental in service 
Webinar 
Office champions 
Other (please specify)  
4. The majority of respondents indicated that oncology is the primary group to discuss 
and prescribe SERMs and AIs for risk reduction. Would you support that primary care 
and Ob/Gyn, with appropriate training, can and should initiate these discussions with 
high risk women? 
Yes 
No 
Other (please specify)  
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5. Many respondents suggested having specific guidelines for discussions with 
members about SERMs and AIs for risk reduction.  
A clinical practice guideline would indicate the mechanism for identifying women at high 
risk, and when that risk status will be reassessed;  
inclusion / exclusion criteria;  
the medication appropriate for the woman based on her menopausal and health risk 
status;  
dosage, and risks/benefits, and alternatives to the medication, 
length of time of medication use;  
and management of side effects.  
Do you agree this forms the basis of a guideline? 
If no, what needs to be included? 
yes 
no 
Other (please specify)  
6. For planning purposes if support is needed for these discussions with members, or the 
woman desires a 2nd opinion, who would we refer to? 
Pharmacy 
Oncology 
Ob/Gyn 
Primary Care physician 
Genetics 
Other (please specify)  
7. Are there other comments you would like to make about developing a guideline on this 
topic at KPCO? 
No 
Yes 
Other (please specify)  
Thank you for your participation in this survey.  If you have questions or comments for 
me that were not addressed please contact me at Linda.m.Kottmann@kp.org, or 303 649 
5581 or KP Skype or Sametime. 
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APPENDIX G 
 
CLINICAL PRACTICE GUIDELINE: KAISER  
PERMANENTE COLORADO 
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